U.S. Application No. 09/486167

International Application No. PCT/BE98/00124

Attorney Docket No. **VANM143.001APC**

Date: February 22, 2000

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 USC 371

International Application No.: PCT/BE98/00124
International Filing Date: August 20, 1998
Priority Date Claimed: August 20, 1997
Title of Invention: PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDES AND THEIR USES IN THE DIAGNOSIS AND/OR THE TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS
Applicant(s) for DO/EO/US: Bernard Knoops, Cedric Hermans, Alfred Bernard, Ruddy Wattiez, Paul Falmagne

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. (X) This is a **FIRST** submission of items concerning a filing under 35 USC 371.

2. (X) This express request to begin national examination procedures (35 USC 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 USC 371(b) and PCT Articles 22 and 39(1).

3. (X) A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date.

4. (X) A copy of the International Application as filed (35 USC 371(c)(2))

   a) () is transmitted herewith (required only if not transmitted by the International Bureau).
   b) (X) has been transmitted by the International Bureau.
   c) () is not required, as the application was filed in the United States Receiving Office (RO/US).

5. (X) Amendments to the claims of the International Application under PCT Article 19 (35 USC 371(c)(3))

   a) () are transmitted herewith (required only if not transmitted by the International Bureau).
   b) () have been transmitted by the International Bureau.
   c) () have not been made; however, the time limit for making such amendments has NOT expired.
   d) (X) have not been made and will not be made.

6. (X) A copy of the International Preliminary Examination Report with any annexes thereto, such as any amendments made under PCT Article 34.

7. (X) An Information Disclosure Statement under 37 CFR 1.97 and 1.98.

8. (X) A FIRST preliminary amendment.

9. (X) International Application as published.

10. (X) PCT Form PCT/IPEA/402.

11. (X) PCT Form PCT/IB/308.

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 NEWPORT CENTER DR 16TH FLOOR NEWPORT BEACH, CA 92660
(949) 760-0404 FAX (949) 760-9502

12. (X) PCT request form.

13. (X) A return prepaid postcard.

14. (X) The following fees are submitted:

				FEES
	BASIC FEE			$840
CLAIMS	**NUMBER FILED**	**NUMBER EXTRA**	**RATE**	
Total Claims	30 - 20 =	10 ×	$18	$180
Independent Claims	1 - 3 =	0 ×	$78	$0
Multiple dependent claims(s) (if applicable)			$260	$260
	TOTAL OF ABOVE CALCULATIONS		$1280	
	TOTAL FEES ENCLOSED			$840

15. (X) The fee for later submission of the signed oath or declaration set forth in 37 CFR 1.492(e) will be paid upon submission of the declaration.

16. (X) A check in the amount of $840 to cover the above fees is enclosed.

17. (X) The Commissioner is hereby authorized to charge only those additional fees which may be required, now or in the future, to avoid abandonment of the application, or credit any overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

Daniel Altman
Signature

Daniel E. Altman
Printed Name

34,115
Registration Number

H:\DOCS\JAH\JAH-2110.DOC
022100

U.S. Application No.	International Application No.	Attorney Docket No.
09/486,167	PCT/BE98/00124	**VANM143.001APC**

#3

Date: August 4, 2000

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on

4-Aug-2000
(Date)

Daniel Altman
Daniel E. Altman, Reg. No. 34,115

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 USC 371

International Application No.: PCT/BE98/00124
International Filing Date: August 20, 1998
Priority Date Claimed: August 20, 1997
Title of Invention: PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS
Applicant(s) for DO/EO/US: Knoops et al.

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

(X) This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.

(X) Copy of Notification of Missing Requirements Under 35 U.S.C. 371 In The United States Designated/Elected Office (DO/EO/US) dated May 4, 2000.

(X) An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)).

(X) An extension of time to respond for two month(s) is hereby requested.

Time Extension Fee:
(X) two months ($190 small entity)

08/18/2000 ERIMANDO 00000139 09486167
01 FC:215 55.00 OP

(X) Small Entity Statement.

(X) A return prepaid postcard.

(X) The fee of $65 for submission of the Declaration after 30 months from the priority under 37 C.F.R. 1.492(e).

08/18/2000 [illegible]
01 FC:[illegible]

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 NEWPORT CENTER DR 16TH FLOOR NEWPORT BEACH, CA 92660
(949) 760-0404 FAX (949) 760-9502

(X) The fee of $65 for submission of the Declaration after 30 months from the priority under 37 C.F.R. 1.492(e).

(X) Fees as calculated below:

FILING FEE PAID ON FEBRUARY 22, 2000		$ 840
FEE FOR EXTENSION OF TIME (LARGE ENTITY)	2 months	$ 380
SURCHARGE 37 CFR 1.16(e)		$ + 130
REMAINDER OF FILING FEE TO BE PAID		$ 440
TOTAL OF ABOVE CALCULATIONS		$ 1790
REDUCTION BY 1/2 FOR FILING BY SMALL ENTITY. Note 37 CFR 1.9, 1.27, 1.28. If applicable, verified statement must be attached.		$ - 895
TOTAL OF $895 SUBTRACT $840 ALREADY PAID =		$ 55
TOTAL FEES SUBMITTED HEREWITH		$ 55

(X) The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 11-1410. A duplicate copy of this sheet is enclosed.

Daniel Altman
Signature

Daniel E. Altman
Printed Name

34,115
Registration Number

SEND ALL CORRESPONDENCE TO:

KNOBBE, MARTENS, OLSON & BEAR, LLP
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660

H:\DOCS\JAH\JAH-3102 DOC:bb
080400

#3

For: **PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS**

VERIFIED STATEMENT (DECLARATION) CLAIMING SMALL-ENTITY STATUS

I, the undersigned, do hereby declare that:

[X] I am an official of the small business concern empowered to act on behalf of the concern identified below:

NAME OF CONCERN: UNIVERSITE CATHOLIQUE DE LOUVAIN
ADDRESS OF CONCERN: Halles Universitaires, Place de l'Université 1, B-1348 Louvain-La-Neuve, BELGIUM

I further declare that the above-identified small business concern qualifies as a small business concern as defined in 13 CFR 121.12, and reproduced in 37 CFR 1.9(d), for purposes of paying reduced fees to the United States Patent and Trademark Office, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both. I further declare that rights under contract or law have been conveyed to and remain with the small business concern identified above with regard to the invention described in the patent or application identified above.

The individual, concern or organization identified above has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license, any rights in the invention to any person who would not qualify as an independent inventor under 37 CFR 1.9(c) if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

If the rights held by the above-identified individual, concern or organization are not exclusive, each individual, concern or organization having rights in the invention are identified below. Each such individual, concern or organization must file separate verified statements averring to their status as small entities.

***NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention averring to their status as small entities. (37 CFR 1.27).**

FULL NAME: UNIVERSITE DE MONS-HAINAUT
ADDRESS: Place du Parc 20, B-7000 Mons, BELGIUM
[ ] INDIVIDUAL [X] SMALL BUSINESS CONCERN [ ] NONPROFIT ORGANIZATION

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small-entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b)).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed.

For: **PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS**

NAME OF PERSON SIGNING: MARCEL CROCHET MARCEL CROCHET
TITLE OF PERSON (if not an owner or individual): Rector Rector
ADDRESS OF PERSON SIGNING: Halles Universitaires, Place de l'Université 1, B-1348 Louvain-La-Neuve, BELGIUM

SIGNATURE: X DATE: 31 Mai 2000

H:\DOCS\JAH\JAH-2147.DOC
022800

VANM143.001APC PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant	:	Knoops, et al.	Group Art Unit Unknown
Int'l Appl. No.	:	PCT/BE98/00124	
Int'l Filing Date	:	August 20, 1998	
For	:	PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS	
Examiner	:	Unknown	

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Preliminary to Examination on the merits, please amend the above-captioned patent application as follows:

IN THE SPECIFICATION

On page 1 of the Specification after the Title of the Invention and before the Field of the Invention, on line 13, please insert --This U.S. National Phase application claims priority under 35 U.S.C. §371 of International Application PCT/BE98/00124, filed August 20, 1998, which claims priority of Belgian application BE 9700692, filed August 20, 1997.--.

On page 21, before Claim 1, please cancel the word "CLAIMS" and substitute therefore --WHAT IS CLAIMED IS:--.

IN THE CLAIMS

1. **(Amended)** An isolated or purified **[Amino acid sequence]**polypeptide **[having]**comprising and amino acid sequence more than 70% **[homology with]**homologous to **[the sequence]** SEQ ID **[NO 2]**NO:2.

2. **(Amended)** **[Amino acid sequence]**The isolated or purified polypeptide according to claim 1, **[having]** more than 85% **[homology with the sequence]**homologous to SEQ ID **[NO 2]**NO:2.

3. **(Amended)** **[Amino acid sequence]**The isolated or purified polypeptide according to claim 1 **[or 2]**, **[having]** more than 95% **[homology with the]**homologous to sequence SEQ ID **[NO 2]**NO:2.

4. **(Amended)** **[Amino acid sequence]**The isolated or purified polypeptide according to **[any one of the preceding claims]**claim 1, **[corresponding to]**comprising SEQ ID **[NO 2]**NO:2 or an immunoreactive portion thereof.

5. **(Amended)** An isolated or purified polynucleotide **[Nucleotide sequence]** encoding the amino acid sequence according to **[any one of the preceding claims]**claim 1 and **[presenting]** more than 70% **[homology with]**homologous to SEQ ID **[NO 1]**NO:1 or its complementary strand.

6. **(Amended)** An isolated or purified polynucleotide **[Nucleotide sequence]** according to claim 5, **[having]** more than 85% **[homology with the sequence]**homologous to SEQ ID **[NO 1]**NO:1 or its complementary strand.

7. **(Amended)** An isolated or purified polynucleotide **[Nucleotide sequence]** according to claim 5 more than 95% **[homology with the sequence]**homologous to SEQ ID **[NO 1]**NO:1 or its complementary strand.

8. **(Amended)** An isolated or purified polynucleotide **[Nucleotide sequence]** according to **[any one of the claims 5 to 7, corresponding to the sequence]**claim 5 comprising SEQ ID **[NO 1]**NO:1, its complementary strand or a portion thereof specific for SEQ ID **[NO 1]**NO:1 and comprising more than 15 base pairs.

9. **(Amended)** A**[V]**vector comprising the **[nucleotide sequence according to any one of the]** polynucleotide of claim**[s]** 5 **[to 8]**.

10. **(Amended)** A purified antibody or an active portion of said antibody **[inhibitor directed against]**that specifically binds to the polypeptide **[amino acid or nucleotide sequence according to any one of the]**of claim**[s]** 1 **[to 8]**.

11. **(Amended)** **[Inhibitor according to claim 10, being an]**The purified antibody, **[preferably]** of claim 2 wherein said antibody is a monoclonal antibody**[, or a portion of said antibody]**.

12. **(Amended)** A **[D]**diagnostic device comprising an element selected from the group consisting of the amino acid sequence **[according to any one of the claims 1 to 4]**of claim 1, the nucleotide sequence **[according to any one of the claims 5 to 8]**of claim 2, the **[inhibitor according to claim 10 or 11]** antibody of claim 10, their portions **[or]**and a mixture thereof.

13. **(Amended)** **[Method]**A method for the *in vitro* detection of lung injuries and diseases or oxidative stress-related diseases and disorders, **[especially inflammatory diseases,]**comprising the steps of:

-isolating a sample from a body fluid of a patient, **[preferably a human patient,]**

[-possibly inhibiting the contaminants present in said sample,]

-**[put in]** contacting said sample with an element selected from the group consisting of the amino acid sequence **[according to any one of the claims 1 to 4]**of claim 1, the nucleotide sequence **[according to any one of the claims 5 to 8]**of claim 5, the **[inhibitor according to claim 10 or 11]** antibody of claim 10, their portions **[or]**and a mixture thereof, and

-detecting a reaction of a molecule present in said sample with said element.

14. **(Amended)** **[Pharmaceutical]**A pharmaceutical composition comprising a pharmaceutically acceptable carrier and an element selected from the group consisting of the amino acid sequence **[according to any one of the claims 1 to 4]**of claim 1, the nucleotide sequence **[according to any one of the claims 5 to 8]**of claim 5, the **[inhibitor according to claim 10 or 11]** antibody of claim 10, their portions **[or]**and a mixture thereof.

15. **(Amended)** **[Use of the pharmaceutical composition according to claim 14 for the manufacture of a medicament for the prevention and/or the treatment of lung injuries or diseases, and of]**The method of claim 13 wherein said oxidative stress-related diseases or disorders**[, such as]**are selected from the group consisting of: specific cardio-vascular diseases **[like arteriosclerosis,]** neurodegenerative disorders **[such as Alzheimer's disease,**

Parkinson's disease, amyotrophic lateral sclerosis,] apoptosis and inflammatory reactions, allergic reactions **[such as asthma, hay fever and eczema,]** high bone mass syndrome, osteopetrosis, osteoporosis-pseudoglioma syndrome, and Bardet-Biedl syndrome 1.

16. **(Amended)** **[Cell]**A cell transformed by the vector according to claim 9 or comprising a partial or total genomic deletion of **[its]**SEQ ID NO:1, or a homologue thereof **[nucleotide sequence according to any one of the claims 5 to 8]**.

17. **(Amended)** **[Non-human]**A non-human transgenic animal,**[preferably a mammal]** transformed by the vector according to claim 9 or comprising a partial or total genomic deletion of **[its]**SEQ ID NO:1, or a homologue thereof **[nucleotide sequence according to any one of the claims 5 to 8]**.

Please add the following claims:

18. The method of claim 13, wherein said oxidative stress-related diseases and disorders are inflammatory diseases.

19. The method of claim 13, further comprising the step of inhibiting the contaminants present in said sample.

20. The method of claim 13, wherein said patient is a human patient.

21. The method of claim 15 wherein said specific cardio-vascular diseases is arteriosclerosis.

22. The method of claim 15 wherein said neurodegenerative disorders are selected from the group consisting of: Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.

23. The method of claim 15 wherein said allergic reactions are selected from the group consisting of: asthma, hay fever and eczema.

24. The transgenic animal of claim 16, wherein said animal is a mammal.

REMARKS

Claims 1-17 have been amended to conform to U.S. practice before the USPTO. Claims 18-24 have been added. Support for added Claims 18-24 can be found in the claims as filed. The Specification has been amended to include the priority international document and to correct minor informalities. No new matter has been added herewith. As a result of the amendments, Claim 1-24 are pending.

This Preliminary Amendment enters a Sequence listing, pages 1-13. Enclosed herewith are: (1) a paper copy of the Sequence Listing, (2) and a computer readable version of the Sequence Listing. In view of the foregoing, the application is believed to fully comply with the Sequence Listing disclosure requirements.

VERIFICATIONS UNDER 37 C.F.R. §1.821(f) & (g)

All of the sequences in the attached Sequence Listing were included in the application as filed. Pursuant to 37 C.F.R. § 1.821(g), no new matter is being added herewith. As required under 37 C.F.R. § 1.821(f), I hereby verify that the data on the computer readable disk and the paper copies of the Sequence Listing submitted herewith are identical.

Conclusion

Should there be any questions concerning this application, the Examiner is invited to contact the undersigned attorney at the telephone number appearing below.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 22 Feb. 2000

By: Daniel Altman

Daniel E. Altman
Registration No. 34,115
Attorney of Record
620 Newport Center Drive
Sixteenth Floor
Newport Beach, CA 92660
(949) 760-0404

H:\DOCS\JAH\JAH-1984.DOC
012500

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: UNIVERSITE CATHOLIQUE DE LOUVAIN
Halles Universitaires
(B) STREET: Place de l' Universite, 1
(C) CITY: LOUVAIN-LA-NEUVE
(E) COUNTRY: BELGIUM
(F) POSTAL CODE (ZIP): B-1348

(A) NAME: UNIVERSITE DE MONS-HAINAUT
(B) STREET: Place du Parc 20
(C) CITY: MONS
(E) COUNTRY: BELGIUM
(F) POSTAL CODE (ZIP): B-7000

(ii) TITLE OF INVENTION: PEROXISOME-ASSOCIATED PEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID PEPTIDE AND THEIR USES IN THE DIAGNOSTIC AND/OR THE TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS

(iii) NUMBER OF SEQUENCES: 19

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 805 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:193..681

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCCAGGAGGC GGAGTGGAAG TGGCCGTGGG GCGGGTATGG GACTAGCTGG CGTGTGCGCC 60

CTGAGACGCT CAGCGGGCTA TATACTCGTC GGTGGGGCCG GCGGTCAGTC TGCGGCAGCG 120

```
GCAGCAAGAC GGTGCAGTGA AGGAGAGTGG GCGTCTGGCG GGGTCCGCAG TTTCAGCAGA      180

GCCGCTGCAG CC ATG GCC CCA ATC AAG GTG GGA GAT GCC ATC CCA GCA           228
              Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ala
                1               5                  10

GTG GAG GTG TTT GAA GGG GAG CCA GGG AAC AAG GTG AAC CTG GCA GAG        276
Val Glu Val Phe Glu Gly Glu Pro Gly Asn Lys Val Asn Leu Ala Glu
        15                  20                  25

CTG TTC AAG GGC AAG AAG GGT GTG CTG TTT GGA GTT CCT GGG GCC TTC        324
Leu Phe Lys Gly Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe
    30                  35                  40

ACC CCT GGA TGT TCC AAG ACA CAC CTG CCA GGG TTT GTG GAG CAG GCT        372
Thr Pro Gly Cys Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala
45                  50                  55                  60

GAG GCT CTG AAG GCC AAG GGA GTC CAG GTG GTG GCC TGT CTG AGT GTT        420
Glu Ala Leu Lys Ala Lys Gly Val Gln Val Val Ala Cys Leu Ser Val
                65                  70                  75

AAT GAT GCC TTT GTG ACT GGC GAG TGG GGC CGA GCC CAC AAG GCG GAA        468
Asn Asp Ala Phe Val Thr Gly Glu Trp Gly Arg Ala His Lys Ala Glu
            80                  85                  90

GGC AAG GTT CGG CTC CTG GCT GAT CCC ACT GGG GCC TTT GGG AAG GAG        516
Gly Lys Val Arg Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu
        95                  100                 105

ACA GAC TTA TTA CTA GAT GAT TCG CTG GTG TCC ATC TTT GGG AAT CGA        564
Thr Asp Leu Leu Leu Asp Asp Ser Leu Val Ser Ile Phe Gly Asn Arg
    110                 115                 120

CGT CTC AAG AGG TTC TCC ATG GTG GTA CAG GAT GGC ATA GTG AAG GCC        612
Arg Leu Lys Arg Phe Ser Met Val Val Gln Asp Gly Ile Val Lys Ala
125                 130                 135                 140

CTG AAT GTG GAA CCA GAT GGC ACA GGC CTC ACC TGC AGC CTG GCA CCC        660
Leu Asn Val Glu Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro
                145                 150                 155

AAT ATC ATC TCA CAG CTC TGA GGCCCTGGGC CAGATTACTT CCTCCACCCC           711
Asn Ile Ile Ser Gln Leu  *
            160

TCCCTATCTC ACCTGCCCAG CCCTGTGCTG GGGCCCTGCA ATTGGAATGT TGGCCAGATT      771

TCTGCAATAA ACACTTGTGG TTTGCGGAAA AAAA                                  805
```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 163 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ala Val Glu Val Phe
 1               5                  10                  15

Glu Gly Glu Pro Gly Asn Lys Val Asn Leu Ala Glu Leu Phe Lys Gly
            20                  25                  30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
        35                  40                  45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Glu Ala Leu Lys
    50                  55                  60

Ala Lys Gly Val Gln Val Val Ala Cys Leu Ser Val Asn Asp Ala Phe
65                  70                  75                  80

Val Thr Gly Glu Trp Gly Arg Ala His Lys Ala Glu Gly Lys Val Arg
                85                  90                  95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu Thr Asp Leu Leu
            100                 105                 110

Leu Asp Asp Ser Leu Val Ser Ile Phe Gly Asn Arg Arg Leu Lys Arg
        115                 120                 125

Phe Ser Met Val Val Gln Asp Gly Ile Val Lys Ala Leu Asn Val Glu
    130                 135                 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Ile Ser
145                 150                 155                 160

Gln Leu  *
```

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 780 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Rattus Rattus

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:136..624

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```
TGCGTCCTAG GCAGCATAGC CGGATCGGTG CTCCGTGCAT CGGCTACTTG GACGTGCGTG      60

GCAGGCAGAG CAGGCCGGAA AGGAGCAGGT TGGGAGTGTG GTGGGGCCCG CAGCTTCAGC     120
```

AGTGCCGCGG TGACTATGGC CCCGATCAAG GTGGGAGACA CCATTCCCTC AGTGGAGGTA 180

TTTGRAGGGG AACCTGGAAA GAAGGTGAAC TTGGCAGAGC TGTTCAAGGA CAAGAAAGGT 240

GTTTTGTTTG GAGTCCCTGG GGCATTTACA CCTGGCTGTT CCAAGACCCA TCTGCCTGGG 300

TTTGTGGAGC AAGCCGGAGC TCYGAAGGCC AAGGGAGCAC AAGTGGTGGC CTGTCTGAGT 360

GTTAATGATG YCTTCGTGAC TGCAGAGTGG GGTCGAGCCC ACCAGGCAGA AGGCAAGGTT 420

CAGCTCCTGG CTGACCCCAC TGGAGCTTTT GGAAAGGAGA CAGATTTACT ACTAGATGAT 480

TCTTTGGTGT CTCTCTTTGG GAATCGTCGG CTAAAAAGGT TCTCCATGGT GATAGACAAG 540

GGCGTAGTAA AGGCACTGAA CGTGGAGCCG GATGGCACAG GCCTCACCTG CAGCCTGGCC 600

CCCAACATCC TCTCACAACT CTGAGGCCCT GACCAGAATG TCCTCTGACT CTCCCATCTC 660

CTCCACCCAG CTCTGGGCCA AAGGCCCAGT ACCTCCTTAC CTGAGGGCCA CTGGAATGGA 720

ACCTTGACAA TATTTCTGCA ATAAACAGTT TAATTTGTGA AAAAAAAAAA AAAAAAAAAA 780

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Rattus Rattus

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:17
(D) OTHER INFORMATION:/product= "Glu or Gly"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:63
(D) OTHER INFORMATION:/product= "Leu or Pro"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:79
(D) OTHER INFORMATION:/product= "Ala or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Ala Pro Ile Lys Val Gly Asp Thr Ile Pro Ser Val Glu Val Phe
1 5 10 15

Xaa Gly Glu Pro Gly Lys Lys Val Asn Leu Ala Glu Leu Phe Lys Asp
20 25 30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
35 40 45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Gly Ala Xaa Lys
50 55 60

Ala Lys Gly Ala Gln Val Val Ala Cys Leu Ser Val Asn Asp Xaa Phe
65 70 75 80

Val Thr Ala Glu Trp Gly Arg Ala His Gln Ala Glu Gly Lys Val Gln
85 90 95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu Thr Asp Leu Leu
100 105 110

Leu Asp Asp Ser Leu Val Ser Leu Phe Gly Asn Arg Arg Leu Lys Arg
115 120 125

Phe Ser Met Val Ile Asp Lys Gly Val Val Lys Ala Leu Asn Val Glu
130 135 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Leu Ser
145 150 155 160

Gln Leu

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 675 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Mouse

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:99..588

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGCTCCGTGC ATCGACGTGC TTGGCAGGCA GAGCAGGCCG GAAAGAAGCA GGTTGGGAGT 60

GTGGCGGAGC CCGCAGCTTC AGCAGCTCCG CGGTGACCAT GGCCCCGATC AAGGTGGGAG 120

ATGCCATTCC CTCAGTGGAG GTATTTGAAG GGGAACCGGG AAAGAAGGTG AACTTGGCAG 180

AGCTGTTCAA GGGCAAGAAA GGTGTTTTGT TTGGAGTCCC TGGGGCATTT ACACCTGGCT 240

GTTCTAAGAC CCACCTGCCT GGGTTTGTGG AGCAAGCTGG AGCTCTGAAG GCTAAGGGAG 300

CGCAGGTGGT GGCCTGTCTG AGCGTTAATG ACGTCTTTGT GATTGAAGAG TGGGGTCGAG 360

CCCACCAGGC AGAAGGCAAG GTTCGGCTCC TGGCTGACCC CACTGGAGCC TTTGGGAAGG 420

CGACAGACTT ATTATTGGAT GATTCTTTGG TGTCTCTCTT TGGGAATCGT CGGCTGAAAA 480

GGTTCTCCAT GGTGATAGAC AACGGCATAG TGAAGGCACT GAACGTGGAG CCAGATGGCA 540

CAGGCCTCAC CTGCAGCCTG GCCCCCAACA TCCTCTCCCA ACTCTGAGGC CCTGGCCAGA 600

TGTCCTCTGA CTCTCCCATC TCTCCCACCC GGCTCTAGGC CAAAAGGCTC GGTACCTCCT 660

TACTGGGAGC CACGT 675

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Mouse

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ser Val Glu Val Phe
1 5 10 15

Glu Gly Glu Pro Gly Lys Lys Val Asn Leu Ala Glu Leu Phe Lys Gly
20 25 30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
35 40 45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Gly Ala Leu Lys
50 55 60

Ala Lys Gly Ala Gln Val Val Ala Cys Leu Ser Val Asn Asp Val Phe
65 70 75 80

Val Ile Glu Glu Trp Gly Arg Ala His Gln Ala Glu Gly Lys Val Arg
85 90 95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Ala Thr Asp Leu Leu
100 105 110

Leu Asp Asp Ser Leu Val Ser Leu Phe Gly Asn Arg Arg Leu Lys Arg
115 120 125

Phe Ser Met Val Ile Asp Asn Gly Ile Val Lys Ala Leu Asn Val Glu
130 135 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Leu Ser
145 150 155 160

Gln Leu

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 469 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..382

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGGTTCG 180

GCTCCTGGCT GATCCCACTG GGGCCTTTGG GAAGGAGACA GACTTATTAC TAGATGATTC 240

GCTGGTGTCC ATCTTTGGGA ATCGACGTCT CAAGAGGTTC TCCATGGTGG TACAGGATGG 300

CATAGTGAAG GCCCTGAATG TGGAACCAGA TGGCACAGGC CTCACCTGCA GCCTGGCACC 360

CAATATCATC TCACAGCTCT GAGGCCCTGG GCCAGATTAC TTCCTCCACC CCTCCCTATC 420

TCACCTGCCC AGCCGTGTGC TGGGGCCCTG CAATTGGAAT GTTGGCCAG 469

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 601 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..514

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGACACA 180

CCTGCCAGGG TTTGTGGAGC AGGCTGAGGC TCTGAAGGCC AAGGGAGTCC AGGTGGTGGC 240

CTGTCTGAGT GTTAATGATG CCTTTGTGAC TGGCGAGTGG GGCCGAGCCC ACAAGGCGGA 300

AGGCAAGGTT CGGCTCCTGG CTGATCCCAC TGGGGCCTTT GGGAAGGAGA CAGACTTATT 360

ACTAGATGAT TCGCTGGTGT CCATCTTTGG GAATCGACGT CTCAAGAGGT TCTCCATGGT 420

GGTACAGGAT GGCATAGTGA AGGCCCTGAA TGTGGAACCA GATGGCACAG GCCTCACCTG 480

CAGCCTGGCA CCCAATATCA TCTCACAGCT CTGAGGCCCT GGGCCAGATT ACTTCCTCCA 540

CCCCTCCCTA TCTCACCTGC CCAGCCCTGT GCTGGGGCCC TGCAATTGGA ATGTTGGCCA 600

G 601

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 604 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..517

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGGTGGG 180

AGATGCCATC CCAGCAGTGG AGGTGTTTGA AGGGGAGCCA GGGAACAAGG TGAACCTGGC 240

AGAGCTGTTC AAGGGCAAGA AGGGTGTGCT GTTTGGAGTT CCTGGGGCCT TCACCCCTGG 300

ATGTTCCAAG GTTCGGCTCC TGGCTGATCC CACTGGGGCC TTTGGGAAGG AGACAGACTT 360

ATTACTAGAT GATTCGCTGG TGTCCATCTT TGGGAATCGA CGTCTCAAGA GGTTCTCCAT 420

GGTGGTACAG GATGGCATAG TGAAGGCCCT GAATGTGGAA CCAGATGGCA CAGGCCTCAC 480

CTGCAGCCTG GCACCCAATA TCATCTCACA GCTCTGAGGC CCTGGGCCAG ATTACTTCCT 540

CCACCCCTCC CTATCTCACC TGCCCAGCCC TGTGCTGGGG CCCTGCAATT GGAATGTTGG 600

CCAG 604

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2710 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:2516..2710

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:2074..2135

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:1932..1970

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:1728..1859

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:802..936

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TCTGTCCCTT AGCGCCCCCG CGGGGGCTTA CCCCATCCCA CTCCATGACC TCCCCTCCCC 60

CCATGGCGAA TTCCCACCTT TCTGTCTTTC ACTCACTTCC TGGAACCGTC CCCAGGGCCT 120

TGGACCTTCC CCCTTCTCCT CCCAAACCTT GTGAGACCCC ATTCCCTTTC TACTTCATCC 180

TGCTCTCAAC TTTTGGGCTC CTCAGAGGCC CTCACCCCTG ACTCTCTCTC CCTACCCACT 240

CTGGTCCCAT GAAGCCCTCA AGTACTCTGG GGATGGATCC TTCCCCCTTC AAAAGATTCC 300

TTCTTTTGTT CTACACCTCC TGGGTGTAGG GGCCTGGACA CCCTCCCCCA ACGTTCCACC 360

TGCCGCTGCC CTTCCTCTTC CTCCTCCTGA GGGTGGGACC CTCAGACCTG GCCAAGATCC 420

TCTCCCTCCA TGTTGTCAGG GACTCCTCCT CACCCCCAAA TACAGCCCTC TAGCCCCTGT 480

CCATTTTATT CCACTCCTTT CCTGTAACCT AGACAGCATG TTATGCAACC CTTTGCGACA 540

CATGGGGAAA CCTTCCCTCC CTTCCTCTGT TGTCACCAAT GGCCCCTTAA GAGGAGCAGG 600

GCCACCTTGA AACTTGGAGG ATATGGGGTA ACCCAGTGGG AGCGGGCAGG GAGGGCCCTT 660

GGAAACTGAC AGGGCTGGAG TATCCTGCTG GGTTTCAGCC CCGGTTCCTG CAGGCACAGC 720

TGCCAGGCTC TCTGTTCACC TTCCTGCCTC TGGTTTGCCC CGGCTCCCTC ACCCCCCTTA 780

CCCTGGAGTC CTTCCTTCTA GGTGGGAGAT GCCATCCCAG CAGTGGAGGT GTTTGAAGGG 840

GAGCCAGGGA ACAAGGTGAA CCTGGCAGAG CTGTTCAAGG GCAAGAAGGG TGTGCTGTTT 900

GGAGTTCCTG GGGCCTTCAC CCCTGGATGT TCCAAGGTGA GGCCCTTCCC CTTCTGAAGA 960

TCAGGACCTG GGGATCTTTT GTGTTGCTCT TAAGTCCTCC ACATAGTCCT GATAGGACTC 1020

CTAAAAAGCA TTTCAGTGCC ATCACAAAAC AAGTAGAGCT GGGTAGAGCT GGGCGCGGTG 1080

GCTCACGCCT GTAATCCCAG CACTTTGGGA GGCCAAGGCG GGTGGATCAC GAGGTCAGGA 1140

GTCCAAAACC AGCCTGGCCA AGATGGTGAA ACCCTGTCTC TACTAAAAAT GCAAAAAAAT 1200

CAGCCGGATA TGGTGGCGGG CGCCTGTAAT CCCAGGTATT GGGGAGGCTG AGGCAGAGAA 1260

TTGCTTGAAC CCAGGAGGCG TAGGTTGCAG TGAGTGGAGA TCGTGCCTCT GCAGTCCAGC 1320

CTGGGTGAAA GAGCGAGACT CCGTCTCAAA ATGAAAAAAA AAAAAGAAAA CAAGTAGAGA 1380

CTGCAAAAAG GGAACAGTAC CGGGAATGTT GGAGAAAAAC ATACTACAAT TAAATCCAAC 1440

ACCCCTGTTG GTCCTGCTAA ATGACAGGCA CTGTGGAAGG TGCTTGGGAC TCAGATAAAT 1500

AAGACAAAGA TCTGCCCATG GAAAGTTCAC GTCTGGACCA TAAGGCATTA GGTTTCATTC 1560

TGAGCTTCCT AGTGGCCAAG GCAAAAAGGA AATAGAATGG TTTAGACAGC TCTCATTGTC 1620

TGATCAAAGG TGTTGAGGCA GAGCACTGAG GAGGGCCTGG AGATAAAGGG TGGGCTGGGG 1680

GTCAGATGCA GTTATCCCTT TGCCGACCCT TTGTTCCCCT TCCTCAGACA CACCTGCCAG 1740

GGTTTGTGGA GCAGGCTGAG GCTCTGAAGG CCAAGGGAGT CCAGGTGGTG GCCTGTCTGA 1800

GTGTTAATGA TGCCTTTGTG ACTGGCGAGT GGGGCCGAGC CCACAAGGCG GAAGGCAAGG 1860

TGAGGTGAGG GGCCTGCAGG GAGTCAGGAC CAGGTAGGAT ATTCTTCTTG TGACCTCTAC 1920

TTTCTCTGCA GGTTCGGCTC CTGGCTGATC CCACTGGGGC CTTTGGGAAG GTGAGTGTTC 1980

CCCTGACCGC CACAGGGACA TGGCGGTGCG GGGAGCAGTG GGGGCCCTTG GCCTCTTCAA 2040

GGATTTCTGA CACTTTTCTC TGTCTCTTCT TAGGAGACAG ACTTATTACT AGATGATTCG 2100

CTGGTGTCCA TCTTTGGGAA TCGACGTCTC AAGAGGTAAA AGTGGAGAGT CCTCTGTGGA 2160

GAAAGTCCTC TGTGGGAGAG AGTCCTCTGT GGGAGAGAGT CCTCTGTGGA GAGGGTCCTC 2220

TGTGGGAAGA GTCGTCTGTG GGGGAGATGT GTGGGAGAGA GTCCTGTGTG GGGAGAGTCT 2280

TCTGTAGGGG AGAGTCCTCT GGGGAGAGAG TCCTGTGTGG GGGAGAGTCC TCTGTGGGGA 2340

GAGTCCTCTG TGTGGAGAGA GTCCTGTGTG GTGGTGAGTC CTCTGTGGGG GAGAGTCCTC 2400

TGTGGGGGGA GTCCTCTCTG GAGTTCTCTT GGGCCCCTGG CTGTTCACTG CCTGTCTCCA 2460

TGCCCAGCCT CCAAGCCCAG GCTGATGCAG CTGGCTGGGC CCCTCTTTCC GGCAGGTTCT 2520

CCATGGTGGT ACAGGATGGC ATAGTGAAGG CCCTGAATGT GGAACCAGAT GGCACAGGCC 2580

TCACCTGCAG CCTGGCACCC AATATCATCT CACAGCTCTG AGGCCCTGGG CCAGATTACT 2640

TCCTCCACCC CTCCCTATCT CACCTGCCCA GCCCTGTGCT GGGGCCCTGC AATTGGAATG 2700

TTGGCCAGAT 2710

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GCCATCCCAG CAGTGGAGGT GTTTG 25

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TTGAACAGCT CTGCCAGGTT CACC 24

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TGGAGGTGTT TGAAGGGGAG CCAG 24

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CAGGTTCACC TTGTTCCCTG GCTC 24

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGGTATGGGA CTAGCTGGCG 20

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CTGGCCAACA TTCCAATTGC AG 22

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATGTTATGCA ACCCTTTGCG ACAC 24

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GTGTTTGAAG GGGAGCCAGG GAAC 24

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGAGACAGGG TTTCACCATC TTGG 24

PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR THE TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS

Field of the invention

The present invention is related to a new peroxisome-associated polypeptide, the nucleotide sequence encoding said polypeptide and portions thereof as well as their uses in the diagnosis of several diseases, especially the diagnosis and/or the treatment of lung injuries and diseases, and of oxidative stress-related disorders.

Background of the invention

The peroxisomes are organelles nearly ubiquitous in eukaryotic cells. They contain enzymes essential for various catabolic and anabolic pathways. Some of these enzymes are expressed constitutively while others can be induced under appropriate conditions. Peroxisomes carry out a variety of essential reactions such as peroxisomal oxidation and respiration, fatty acid beta-oxidation, cholesterol and dolichol metabolism, ether-phospholipid synthesis, and glyoxylate and pipecolic acid metabolism.

The peroxisomal respiratory pathway is based upon the formation of hydrogen peroxide by a collection of oxidases and the decomposition of the H_2O_2 by catalase. These reactions are responsible for 20% of oxygen consumption in liver, and several oxidases have been identified in peroxisomes. Ethanol elimination via catalase in peroxisomes may be significant in addition to the oxidation via cytosolic alcohol dehydrogenase.

The peroxisomal beta-oxidation system catalyses the beta-oxidative chain shortening of a specific set of compounds which can not be handled by mitochondria : very long chain fatty acids, di- and trihydroxycholestanoic acids, pristanic acid, long chain dicarboxylic acids, several prostaglandins, several leukotrienes, 12- and 15-hydroxyeicosatetraeonic acid, and several mono- and polyunsaturated fatty acids, which are of direct diagnostic relevance for some peroxisomal disorders.

Peroxisomes play also a major role in the synthesis of cholesterol and other isoprenoids. Fibroblasts from patients affected by disorders of peroxisome biogenesis show low capacity to synthesise cholesterol.

Two enzyme activities responsible for introduction of the characteristic ether linkage in ether-linked phospholipids (dihydroacetonephosphate acyltransferase (DHAPAT) and alkyldihydroxyacetonephosphate synthase (alkyl-DHAP synthase)) are localised in peroxisomes. These enzymes are not yet cloned. As demonstrated by the identification of patients with deficiency of either DHAPAT or alkyl-DHAP synthase with severe clinical abnormalities, ether-phospholipids are of major importance in humans.

Peroxisomes are able to detoxify glyoxylate via alanine/glyoxylate aminotransferase. The deficiency of this cloned enzyme causes hyperoxaluria type I.

L-pipecolate is a minor metabolite of L-lysine and is catabolised by the L-pipecolate oxidase localised in peroxisomes. The enzyme is deficient in cerebro-hepato-renal (Zellweger) syndrome.

In human, the importance of peroxisomes was emphasised by a number of inherited diseases involving either a defect in the biogenesis of peroxisomes or a deficiency of one (or more) peroxisomal enzymes. So far, 12 different peroxisomal disorders have been described and most of them are lethal.

A wide variety of chemicals have been showed to produce peroxisome proliferation and induction of peroxisomal and microsomal fatty acids-oxidising enzymes activities in rats and mice. Several peroxisomes proliferators have been shown to increase the incidence of liver tumours in these species. Proposed mechanisms of liver tumour formation by peroxisomes proliferators include induction of sustained oxidative stress.

Therefore, newly identified molecules associated with peroxisomes could be used for the development of diagnostic tools and possibly for the improvement of several therapeutical applications of various diseases associated with peroxisomal disorders. In addition, it is useful to identify the molecules present in specific organs like the lung and which may be used as specific markers of inflammatory diseases as well as lung injuries or diseases.

Summary of the invention

The Inventors have isolated and purified a new sequence of a low molecular weight human broncho-alveolar polypeptide. Said mammal, preferably human, protein or polypeptide (hereafter identified as B18hum protein) has been sequenced and its corresponding genomic DNA (SEQ ID NO 8) and cDNA (SEQ ID NO 1) have been identified. Similarly, the corresponding nucleotide and amino acid sequence from a rat (SEQ ID NO 3 and 4) and from a mouse (SEQ ID NO 5 and 6) have been obtained.

Said sequences present several homologies with other peroxisomal proteins of yeast and comprise a carboxy-terminal tripeptide SQL which is necessary for the specific targeting and translocation of several proteins into the peroxisome.

Therefore, the present invention is related to a new isolated and purified polypeptide sequence having a amino acid sequence which presents more than 70% homology, advantageously more than 85% homology, more preferably more than 95% homology, with the amino acid sequence SEQ ID NO 2.; Said amino acid sequence is advantageously obtained from a mammal, preferably from a rat, a mouse or a human.

The present invention is also related to the isolated and purified polypeptide sequence corresponding to the amino acid sequence SEQ ID NO 2 or a portion thereof, preferably an immunoreactive portion (putative immunogenic domain or T or B cell epitopes).

Said portions are advantageously comprised between :

- Glutamic acid position 13 - Glutamic acid position 27
- Alanine position 26 - Leucine position 36

- Alanine position 42 - Glutamic acid position 57
- Glutamic acid position 57 - Valine position 69
- Valine position 80 - Leucine position 97
- Arginine position 95 - Leucine position 112
- Serine position 118 - Serine position 129
- Valine position 137 - Threonine position 150

Preferably, said portion has more than 10, 20, 30, 50 or 70 amino acids. Specific portions of the amino acid sequence SEQ ID NO 2 are also portions of more than 70 amino acids which present at least 80% of the proteinic activity (see example 5) of the complete SEQ ID NO 2 sequence. Therefore, the amino acid sequence according to the invention can be partially deleted while maintaining its activity, preferably its anti-oxidative activity, which will be described hereafter.

According to the invention, the amino acid sequence SEQ ID NO 2 presents a pI of 7.16 and a molecular weight of 17047 Dalton as hereafter defined by bidimensional electrophoresis.

The present invention is also related to the nucleotide sequence encoding the amino acid sequence according to the invention and its regulatory sequences upstream said coding sequence. A nucleotide sequence encoding the polypeptide according to the invention is a genomic DNA (see SEQ ID NO 10), a cDNA (see SEQ ID NO 1) or a mRNA, possibly comprising said upstream regulatory sequence. Advantageously, said nucleotide sequence presents more than 70%, advantageously more than 85%, more preferably more than 95% homology with SEQ ID NO 1 or its complementary strand.

According to a preferred embodiment of the present invention, said nucleotide sequence corresponds to the nucleotide sequence SEQ ID NO 1, its complementary strand or a portion thereof.

"A portion of the nucleotide sequence SEQ ID NO 1" means any nucleotide sequence of more than 15 base pairs (such as a primer, a probe or an antisense nucleotide sequence) which allow the specific identification, reconstitution or blocking of the complete nucleotide sequence SEQ ID NO 1 (including its regulatory sequences upstream the coding sequence).

Said portions allow the specific identification, reconstitution or blocking by specific hybridisation with the nucleotidic sequence SEQ ID NO 1, preferably under standard stringent conditions, with sequences like probes or primers possibly labelled with a compound (radioactive compound, enzyme, fluorescent marker, etc.), and can be used in a specific diagnostic or dosage method like probe hybridisation (see Sambrook et al., §§ 9.47-9.51 in *Molecular Cloning : A Laboratory Manual*, Cold Spring Harbor, Laboratory Press, Cold Spring Harbor, New York (1989)), genetic amplification (like PCR (US patent 4,683,195), LCR (Wu et al., *Genomics* 4, pp. 560-569), CPR (US patent 5,011,769)).

Exemplary stringent hybridisation conditions are as follows : hybridisation at 42 °C in 50% formamide 5x SSC, 20 mM sodium phosphate, pH 6.8 washing in 0.2x SSC at 55 °C. It is understood by those skilled in the art that variation of these conditions occur based on the length and GC nucleotide content of the sequence to be hybridised. Formulas standard in the art are appropriated for

determining exact hybridisation conditions (see Sambrook et al.

Preferred examples of said nucleotide portions are as follows :

	Sequence	Position
5'-gccatcccagcagtggaggtgtttg-3'	(SEQ ID NO 11)	217-241
5'-ttgaacagctctgccaggttcacc-3'	(SEQ ID NO 12)	261-284
5'-tggaggtgtttgaaggggagccag-3'	(SEQ ID NO 13)	230-253
5'-caggttcaccttgttccctggctc-3'	(SEQ ID NO 14)	247-270
5'-gggtatgggactagctggcg-3'	(SEQ ID NO 15)	33-52
5'-ctggccaacattccaattgcag-3'	(SEQ ID NO 16)	747-768

and the sequences of respectively 601 (SEQ ID NO 8), 604 (SEQ ID NO 9) and 469 (SEQ ID NO 7) base pairs corresponding to specific mRNA alternative splicing of the B18 human nucleotide sequence as described in Figure 4 (the known genomic sequence incorporating several introns and exons is represented in the sequence SEQ ID NO 10).

Said sequences may be used for a genetic amplification or a probe hybridisation as above-described.

The present invention is also related to a vector comprising the necessary elements for the injection, transfection or transduction of cells and having incorporated one or more of the nucleotide sequences according to the invention. The vector according to the invention is selected from the group consisting of viruses, plasmids, phagemides, cationic vesicles, liposomes or a mixture thereof. Said vector may comprise also one or more adjacent regulatory sequences (such as promoter(s), secretion and termination signal sequence(s)), advantageously operably linked to the nucleotide sequence according to the invention.

The present invention is also related to the cell transformed by said vector and expressing the polypeptide according to the invention.

The nucleotide sequence according to the invention can be also introduced in said cell by the formation of $CaPO_4$-nucleic acid precipitate, DEAE-dextran-nucleic acid complex or by electroporation.

Another aspect of the present invention is related to an inhibitor of the polypeptide according to the invention or the nucleotide sequence according to the invention (including the upstream sequences like promoter-operator regulatory sequence which may be inhibited by a cis- and/or transactivating repressor). Said inhibitor is advantageously an antibody or a fragment of said antibody such as an hypervariable portion of said antibody directed against the amino acid or nucleotide sequence of the polypeptide according to the invention. Other examples of inhibitors according to the invention are antisense nucleotide sequences which allow the blocking of the expression of the nucleotide sequence according to the invention.

Another aspect of the present invention is related to a diagnostic device (such as a diagnostic kit or a chromatographic column) comprising an element selected from the group consisting of the amino acid sequence of said polypeptide, its nucleotide sequence, and/or the inhibitor according to the invention or a fragment thereof as above-described. Said diagnostic device may comprise also necessary reactants and media for the diagnostic and/or dosage of the nucleotide and/or amino acid sequence of the polypeptide according to the invention, which are based upon the method selected from the group consisting of

in situ hybridisation, hybridisation by labelled antibodies, especially RIA (Radio Immuno Assay) or ELISA (Enzymes Linked Immuno-Sorbent Assay) technologies, detection upon filter, upon solid support, in solution, in sandwich, upon gel, dot blot hybridisation, Northern blot hybridisation, Southern blot hybridisation, isotopic or non-isotopic labelling (by immunofluorescence or biotinilised probes), genetic amplification, (especially by PCR or LCR), double immunodiffusion technique, counter-electrophoresis technique, haemagglutination or a mixture thereof.

Another aspect of the present invention concerns a diagnosis method wherein a biological sample from the patient, such as cephalo-rachidian fluid, serum, blood, plasma, urine, broncho-alveolar lavage, stomach lavage, etc., is isolated from the patient, and is put in contact with the diagnostic device according to the invention for the diagnosis or the monitoring of an injury or a disease, preferably a lung injury or an oxidative stress-related disorder, affected by the presence of pro-oxidant agent or oxidative stress such as specific cardio-vascular diseases like arteriosclerosis, neurodegenerative disorders (Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis), apoptosis, inflammatory reactions, allergic reactions such as asthma, hay fever and eczema, high bone mass syndrome, osteopetrosis, osteoporosis-pseudoglioma syndrome, and Bardet-Biedl syndrome 1. Said diagnosis and monitoring upon one or more biological samples obtained from several tissues from the patient can be advantageously obtained by one or more of the methods above-described, which could be adapted

according to the specific biological sample by the person skilled in the art.

Therefore, the product according to the invention could be used as a marker for the above-identified injuries, diseases or disorders in a broad spectrum of tissues as shown in the enclosed Figure 1.

A further aspect of the present invention is related to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an element selected from the group consisting of the nucleotide sequence, the amino acid sequence of the polypeptide according to the invention, the inhibitor directed against said sequences and/or one or more portions thereof.

A last aspect of the present invention is related to the use of the pharmaceutical composition according to the invention for the manufacture of a medicament in the treatment and/or the prevention of lung injuries and/or diseases or of oxidative stress-related disorders.

The present invention is also related to a prevention and/or treatment method of a patient, especially a human patient, preferably affected by lung injuries and/or diseases or by oxidative stress-related disorders, wherein a sufficient amount of the pharmaceutical composition according to the invention is administered to said patient in order to treat, avoid and/or reduce the symptoms of said injuries and/or diseases.

Other injuries and/or diseases which can be prevented and/or treated are injuries and/or diseases affected by the presence of pro-oxidant agents or oxidative stress, such as specific cardio-vascular diseases like arteriosclerosis, neurodegenerative disorders such as

Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, apoptosis and inflammatory reactions and some allergic reactions such as asthma, hay fever and eczema, high bone mass syndrome, osteopetrosis, osteoporosis-pseudoglioma syndrome, and Bardet-Biedl syndrome 1.

The pharmaceutically acceptable carrier according to the invention is any compatible non-toxic substance suitable for administering the composition according to the invention to a human patient. Pharmaceutically acceptable carriers according to the invention suitable for oral administration are the ones well known by the person skilled in the art, such as tablets, coated or non-coated pills, capsules, spray-gas, patches, gels, solutions or syrups. Pharmaceutically acceptable carriers vary according to the mode of administration (intravenous, intramuscular, subcutaneous, parenteral, etc.), and may comprise also adjuvants well known by the person skilled in the art to increase, reduce and/or regulate humoral, local and/or cellular response of the immune system.

The pharmaceutical composition according to the invention may be prepared by the methods, generally applied by the person skilled in the art in the preparation of various pharmaceutical compositions, wherein the percentage of the active compound/pharmaceutically acceptable carrier can vary within very large ranges, only limited by the tolerance of the patient to said pharmaceutical composition, and wherein the limits are particularly determined by the frequency of administration and the possible side-effects of the active compounds or its pharmaceutically acceptable carrier.

Another aspect of the invention is related to the use of the diagnostic device according to the invention for performing upon the patient or upon a biological fluid obtained from the patient, a diagnosis, a dosage and/or a monitoring of the above-mentioned injuries or diseases or oxidative stress-related disorders affecting the patient.

A further aspect of the present invention is related to a cell or a non-human animal, preferably a mammal such as a mouse or a rat, transformed by the vector according to the invention and overexpressing the polypeptide according to the invention, or a non-human animal, preferably a mammal such as a mouse or a rat, genetically modified by a partial or total deletion of its genomic sequence encoding the polypeptide according to the invention (knock-out non-human mammal) and obtained by methods well known by the person skilled in the art such as the one described by Kahn et al. (*Cell*, Vol. 92, pp. 593-596 (March 1998)).

Other examples of genetically modified non-human animals according to the invention may be a transgenic non-human animal comprising an inhibitor according to the invention, preferably an antisense nucleic acid sequence complementary to the nucleotide sequence according to the invention so placed as to be transcribed into antisense mRNA which is complementary to the nucleotide sequence according to the invention and which hybridises to said nucleotide sequence, thereby reducing or blocking its translation.

Further aspects of the present invention will be described in the enclosed non-limiting examples in reference to the following Figures.

Brief description of the drawings

Figure 1 represents a dot blot analysis of mRNA encoding the polypeptide according to the invention in various types of human tissues.

Figure 2 represents a Northern blot analysis of mRNA encoding the polypeptide according to the invention in a rat lung after administration of lipopolysaccharides (LPS) inducing an inflammatory reaction of the lung.

Figure 3 represents a Northern blot analysis of mRNA encoding the polypeptide according to the invention in a rat lung after intraperitoneal injection of pneumotoxicants.

Figure 4 is a schematic representation of the human genomic sequence, the complete cDNA sequence and the corresponding amino acid sequence.

Figure 5 represents respectively the alignment of the sequences of the human B18 polypeptide according to the invention with the corresponding rat and mouse sequences.

Example 1 : Homology between the B18 polypeptide according to the invention with other known nucleotide or amino acid sequences

The BLAST 2.0 software (gapped BLAST at the NCBI Internet site) was used for searching for homologies between human B18 (162 amino acids) and known polypeptides in databases (GenBank, SwissProt). Said search did not give perfect alignment with known peptides from different species (Table 1). Homologies of the human B18 cDNA (805 nucleotides) with GenBank, EMBL, DDBJ and PDB deposited

nucleotide sequences (Table 2) and GenBank Expression Sequence TAGS (ESTs) were noted.

Table 1 : Homologies of the B18 proteins (162 amino acid) with other proteins

Name	NCBI ID	Identity (%) Homology (%)
Membrane protein (synechocystis sp.)	1652859	57/129(44%) 81/129(62%)
Peroxisomal-like protein (Aspergillus fumigatus)	2769700	56/176(31%) 90/176(50%)
Haein HI0572 hypothetical protein(Haemophilus influenzae)	1723174	53/146(36%) 80/146(54%)
PMP20 (Schizosaccharomyces pombe)	AJ002536	54/161(33%) 85/161(52%)
Peroxisomal membrane protein A (PMP 20)(Candida boidinii)	130360	59/170(34%) 89/170(51%)
Peroxisomal membrane protein B (PMP 20)(Candida boidinii)	130361	58/170(34%) 88/170(51%)
Putative peroxisomal protein PMP from yeast (Saccharomyces cerevisiae)	1709682	41/138(29%) 72/138(51%)
Alkylhydroperoxide reductase C22 protein (Escherichia coli)	P26427	36/126(28%) 58/126(45%)

Table 2

Name	Access NO	Identity
Human mRNA down-regulated in cells infected by adenovirus 5	U82616	259/263 (98%)
Human mRNA down-regulated in cells infected by adenovirus 5	U82615	300/321 (93%)

In the Table 2, an identity of 98% has been obtained with the alignment of 259 nucleotides of CDNA B18, which comprises in its totality 805 nucleotides, with 263 nucleotides of U82616 CDNA. A similar identity has been obtained with the U82615 sequence.

The sequence SEQ ID NO 1 comprising 805 nucleotides presents a homology with several EST sequences obtained from a human and from a mouse, having the following references :

Human :

AA130751, N42215, W38597, N91311, N68467, AA187737, N68916, W00593, R88950, AA181884, H20154, H66666

Mouse :

AA220019, AA123351, AA087129, AA255021, AA249897, W71344

Example 2 : Tissue detection

A human RNA master Blot (Clontech) containing 100-500 ng of poly-A + human RNA in each dot (normalised to the mRNA expression levels of eight different housekeeping genes) was hybridised with a 554 bp-long B18 probe labelled with ^{32}P, and quantified using Phosphorimaging Technology. As shown in Figure 1, B18 mRNA is present in all tissues examined but predominantly in trachea, lung, kidney, thyroid gland, stomach, colon, heart and some regions of the brain. Highest expression has been noted in the thyroid tissue. This presence is probably correlated with the possible antioxidant activity of the B18 polypeptide according to the invention.

Example 3 : Inflammatory reaction

Figure 2 represents a Northern blot analysis of rat lung mRNA after 6, 48 and 72 hours after

lipopolysaccharides (LPS) instillation inducing an inflammatory reaction in the lung.

A Northern blot containing 15 μg of total RNA in each lane was hybridised with a 225 bp-long rat B18 probe, stripped and reprobed with a 572 bp-long rat β-actin probe, both labelled with ^{32}P. Northern blot was quantified using Phosphorimaging Technology and the B18 mRNA data were normalised to β-actin mRNA level.

Example 4 : Pneumotoxic reaction

Figure 3 represents a Northern blot analysis of rat lung mRNA after intraperitoneal injection of pneumotoxicants (4-ipomeanol,1-(3-fyryl)-4-hydroxypentanone (IPO), methylcyclopentadienyl manganese tricarbonyl (MMT) or alpha naphtylthiourea (ANTU)). These agents are known to induce in the lung acute lesions of Clara (IPO) and alveolar cells (MMT) as well as increasing the permeability of the alveolar/blood barrier (ANTU). A Northern blot containing 15 μg of total RNA in each lane was hybridised with a 225 bp-long rat B18 probe, stripped and reprobed with a 572 bp-long β-actin probe both labelled with ^{32}P. The Northern blot was quantified using Phosphorimaging Technology and rat B18 mRNA data were normalised to β-actin mRNA level.

Example 5 : Proteinic activity of the B18 polypeptide

An amino analysis of the complete human B18 amino acid sequence shows that said polypeptide presents specific portions showing an homology with other anti-oxidant enzymes (starting from a Leucine at position 36 until a Cysteine at position 47) and an other portion

having an important homology with beta chains of ATP synthase (starting from a Glutamic acid at position 13 until a Glycine in position 38).

Furthermore, the B18 amino acid sequence according to the invention shows an important homology with an *Aspergillus fumigatus* allergen (34% identity and 60% homology by using clustal V sequence alignment), especially upon the portion of said B18 polypeptide having possible antioxidant properties. Therefore, it is possible that a peroxisomal protein (possibly homologous to B18 protein) is able to induce and to bind IgE from patients sensitised to *Aspergillus fumigatus* peroxisomal proteins after an induction of the patient immune system with *Aspergillus fumigatus* allergen. This mechanism can be compared to a reaction obtained with the manganese superoxide dismutase (MnSOD) wherein the human MnSOD is able to bind to IgE from patients sensitised to *Aspergillus fumigatus* MnSOD.

Furthermore, the Inventors have identified a portion of the B18 human polypeptide which presents an homology with a Cyclophilin-binding domain of *Candida boidinii* PMP20 (receptor of the immuno-suppressant drug cyclosporine A). Said possible Cyclophilin-binding domain is starting from the Threonine in position 150 until the Leucine in position 161.

Example 6 : B18 human gene and mRNA alternative splicing

As represented in the enclosed Figure 4, the Inventors have identified upon the genomic DNA (SEQ ID NO 10) 5 exons and 5 introns. By RT-PCR (using primers 5'-gggtatgggactagctggcg-3' and 5'-ctggccaacattccaattgcag-3') and according to the genomic sequence, 4 different cDNAs corresponding to the transcription of the said genomic DNA

have been identified in human lung and in human brain. A first cDNA of 736 bp corresponds to the cDNA encoding the complete amino acid sequence of the B18 protein according to the invention. However, 3 other cDNAs of 601, 604 and 469 bp were also identified, and comprise specific splicings of one or more exons.

Therefore, another aspect of the present invention is related to said specific portions of the complete genomic or CDNA nucleotide sequence according to the invention or to specific portions of the complete amino acid sequence of the B18 protein according to the invention, which could be used also as specific markers of the B18 activity, preferably the anti-oxidative activity.

Example 7 : Knock-out mouse

Exons of a mouse genomic sequence encoding the B18 polypeptide according to the invention have been deleted by homologous recombination. Said homologous recombination has been obtained with a genetic sequence comprising a neomycin resistant gene. The targeting vector with said gene and a ,thymidine kinase (in order to eliminate non-homologous recombinants with ganciclovir) has been prepared. Said recombination was used for the deletion of one or more exons of the B18 polypeptide. After electroporation of ES cells with the targeting vector, positive clones having incorporated homologous recombination were identified by Southern blot with labelled probes. Aggregation of said positive clones with a morula from a Swiss pseudo-pregnant mouse produces several chimeric mice which survive after birth. Several homozygote mice are obtained by cross-breeding and are used as a model for the above-mentioned diseases.

Similar experiments may be done with another mammal whose B18 sequence is known (the B18 sequence of a mouse and a rat and their alignment with the human sequence is shown in the enclosed Figure 5).

Example 8 : Chromosome localisation of human B18 gene

Radiation hybrid clones (GeneBridge 4 Radiation Hybrid Panel, Research Genetics) were used for performing chromosome localisation by PCR with two different pairs of primers (5'-caggttcaccttgttccctggctc-3' (SEQ ID NO 14), 5'-atgttatgcaacccttgcgacac-3' (SEQ ID NO 17) and 5'-gtgtttgaaggggagccagggaac-3' (SEQ ID NO 18), 5'-agagacagggtttcaccatcttgg-3' (SEQ ID NO 19)).

The Inventors have located B18 genomic sequence on human chromosome 11q13. B18 gene has been located 7.15-6.1 cR from marker D11S913 between markers D11S1963 and D11S4407 (Genome Database internet site).

Unknown genes linked to different disorders have been localised in the same region of chromosome 11. Therefore, B18 gene is possibly associated with these disorders:

- atopy (atopic hypersensitivity: asthma, hay fever and eczema; MIM n°147050 at OMIM of NCBI internet site),
- high bone mass syndrome(MIM n°601884),
- osteopetrosis (MIM n°259700),
- osteoporosis-pseudoglioma syndrome (MIM n°259770) and
- Bardet-Biedl syndrome 1 (MIM n°209901).

CLAIMS

1. Amino acid sequence having more than 70% homology with the sequence SEQ ID NO 2.

2. Amino acid sequence according to claim 1, having more than 85% homology with the sequence SEQ ID NO 2.

3. Amino acid sequence according to claim 1 or 2, having more than 95% homology with the sequence SEQ ID NO 2.

4. Amino acid sequence corresponding to SEQ ID NO 2 or a portion thereof selected from the group consisting of the sequences comprised between:

- the glutamic acid in position 13 and the glutamic acid in position 27,
- the alanine in position 26 and the leucine in position 36,
- the alanine in position 42 and the glutamic acid in position 57,
- the glutamic acid in position 57 and the valine in position 69,
- the valine in position 80 and the leucine in position 97,
- the arginine in position 95 and the leucine in position 112,
- the serine in position 118 and the serine in position 129,
- the valine in position 137 and the threonine in position 150,

- the glutamic acid in position 13 and the cysteine in position 47,
- the glutamic acid in position 13 and the glycine in position 38, and
- the leucine in position 36 and the cysteine in position 47,
- and the treonine in position 150 and the leucine in position 161.

5. Nucleotide sequence encoding the amino acid sequence according to any one of the preceding claims and presenting more than 70% homology with SEQ ID NO 1 or its complementary strand.

6. Nucleotide sequence according to claim 5, having more than 85% homology with the sequence SEQ ID NO 1 or its complementary strand.

7. Nucleotide sequence according to claim 5 more than 95% homology with the sequence SEQ ID NO 1 or its complementary strand.

8. Nucleotide sequence corresponding to the sequence SEQ ID NO 1, its complementary strand or a portion thereof selected from the group consisting of SEQ ID n° 7, SEQ ID n°8, SEQ ID n°9, SEQ ID n°11, SEQ ID n°12, SEQ ID n°13, SEQ ID n°14, SEQ ID n°15 and SEQ ID n°16.

9. Vector comprising the nucleotide sequence according to any one of the claims 5 to 8.

10. Inhibitor directed against the amino acid or nucleotide sequence according to any one of the claims 1 to 8.

11. Inhibitor according to claim 10, being an antibody, preferably a monoclonal antibody, or a portion of said antibody.

12. Diagnostic device comprising an element selected from the group consisting of the amino acid

sequence according to any one of the claims 1 to 4, the nucleotide sequence according to any one of the claims 5 to 8, the inhibitor according to claim 10 or 11, their portions or a mixture thereof.

13. Method for the in vitro detection of lung injuries and diseases or oxidative stress-related diseases and disorders, especially inflammatory diseases, comprising the steps of :

- isolating a sample from a body fluid of a patient, preferably a human patient,
- possibly inhibiting the contaminants present in said sample,
- put in contact said sample with an element selected from the group consisting of the amino acid sequence according to any one of the claims 1 to 4, the nucleotide sequence according to any one of the claims 5 to 8, the inhibitor according to claim 10 or 11, their portions or a mixture thereof, and
- detecting a reaction of a molecule present in said sample with said element.

14. Pharmaceutical composition comprising a pharmaceutically acceptable carrier and an element selected from the group consisting of the amino acid sequence according to any one of the claims 1 to 4, the nucleotide sequence according to any one of the claims 5 to 8, the inhibitor according to claim 10 or 11, their portions or a mixture thereof.

15. Use of the pharmaceutical composition according to claim 14 for the manufacture of a medicament for the prevention and/or the treatment of lung injuries or diseases, and of oxidative stress-related diseases or disorders, such as specific cardio-vascular diseases like arteriosclerosis, neurodegenerative disorders such as Alzheimer's disease, Parkinson's disease, amyotrophic

24
4

lateral sclerosis, apoptosis and inflammatory reactions, allergic reactions such as asthma, hay fever and eczema, high bone mass syndrome, osteopetrosis, osteoporosis-pseudoglioma syndrome, and Bardet-Biedl syndrome 1.

16. Cell transformed by the vector according to claim 9 or comprising a total deletion of its nucleotide sequence according to any one of the claims 5 to 8.

17. Non-human animal, preferably a non-human mammal, transformed by the vector according to claim 9 or comprising a total deletion of its nucleotide sequence according to any one of the claims 5 to 8.


human DNA 500 ng
human DNA 100 ng
fetal lung
fetal thymus
fetal spleen
fetal liver
fetal kidney
fetal heart
fetal brain
placenta
trachea
lung
appendix
bone marrow
lymph node
penpheral leukocyte
thymus
spleen
small intestine
liver
kidney
mammary gland
salivary gland
thyroid gland
adrenal gland
pituitary gland
pancreas
ovary
testis
stomach
prostate
uterus
bladder
colon
skeletal muscle
aorta
heart
spinal cord
subthalamic nucleus
thalamus
temporal lobe
substantia nigra
putamen
occipital lobe
medulla oblongata
hippocampus
frontal lobe
cerebral cortex
cerebellum
caudate nucleus
amygdala
whole brain
0
100000
200000
300000
400000
500000
600000
700000
800000
B18 mRNA (arbitrary units)

FIG.1


B18 mRNA/beta-actin mRNA
(arbitrary units)
300
250
200
150
100
50
0
Contr
LPS 6h
LPS 48h
LPS 72h
B18 mRNA

FIG.2


B18 mRNA/beta-actin mRNA
(arbitrary units)
250
200
150
100
50
0
Cont
IPO
ANTU
MMT
Cont
IPO
ANTU
MMT

FIG.3


Gene (chromosome 11q12-13)
1 2 3 4 5 6
EXONS
5'
3'
mRNAs
800
670
668
530
Proteins
ATPase-β
A.O.
PRX
17 kDa
12.3 kDa
12.3 kDa
7.7 kDa

FIG.4

CLUSTAL V alignment of human and rat B18 amino acid sequences (Identity: 90%, Homology: 97.5%):

```
B18hum      MAPIKVGDAIPAVEVFEGEPGNKVNLAELFKGKKGVLFGVPGAFTPGCSK = SEQIDNO1
B18rat      MAPIKVGDTIPSVEVFEGEPGKKVNLAELFKDKKGVLFGVPGAFTPGCSK
            ********.**.*********.*********.******************

B18hum      THLPGFVEQAEALKAKGVQVVACLSVNDAFVTGEWGRAHKAEGKVRLLAD
B18rat      THLPGFVEQAGALKAKGAQVVACLSVNDVFVTAEWGRAHQAEGKVQLLAD
            ********** ****** ********** ***.******.*****.****

B18hum      PTGAFGKETDLLLDDSLVSIFGNRRLKRFSMVVQDGIVKALNVEPDGTGL
B18rat      PTGAFGKETDLLLDDSLVSLFGNRRLKRFSMVIDKGVVKALNVEPDGTGL
            ******************.************.. *.**************

B18hum      TCSLAPNIISQL
B18rat      TCSLAPNILSQL
            ********.***
```

FIG.5a

CLUSTAL V alignment of human and mouse B18 amino acid sequences (Identity: 91%, Homology: 96%):

```
B18hum      MAPIKVGDAIPAVEVFEGEPGNKVNLAELFKGKKGVLFGVPGAFTPGCSK
B18mouse    MAPIKVGDAIPSVEVFEGEPGKKVNLAELFKGKKGVLFGVPGAFTPGCSK
            ***********.*********.****************************

B18hum      THLPGFVEQAEALKAKGVQVVACLSVNDAFVTGEWGRAHKAEGKVRLLAD
B18mouse    THLPGFVEQAGALKAKGAQVVACLSVNDVFVIEEWGRAHQAEGKVRLLAD
            ********** ****** ********** **  ******.**********

B18hum      PTGAFGKETDLLLDDSLVSIFGNRRLKRFSMVVQDGIVKALNVEPDGTGL
B18mouse    PTGAFGKATDLLLDDSLVSLFGNRRLKRFSMVIDNGIVKALNVEPDGTGL
            ******* ***********.************...***************

B18hum      TCSLAPNIISQL
B18mouse    TCSLAPNILSQL
            ********.***
```

CLUSTAL V alignment of human and rat cDNA sequences (identity: 612/780, 78.5%):

```
B18hum      GCCAGGAGGCGGAGTGGAAGTGGCCGTGGGGCGGGTATGGGACTAGCTGG
B18rat      --------------TG--------CGTC--------------CTAGGCAG
                        **        ***                ****   *

B18hum      CGTGTGCGCCCTGAGACGCTCAGCGGGCTATATACTCGTCGGTGGGGCCG
B18rat      CATA---GCC---GGA---TCGGTGCTCCGTGCATCGGCTACTTGGAC--
            * *    ***    **   ** * *  *  *  *   *    * ** *

B18hum      GCGGTCAGTCTGCGGCAGCGGCAGCAAGACGGTGCAGTGAAGGAGAGTGG
B18rat      -------GTGCGTGGCAGGCAGAGCAGGCCGG---AAAGGAGCAGGTTGG
                ** * *****    **** * ***   *  * ** **  ***
```

FIG.5b

```
B18hum      GCGTCTGGCGGGGTCCGCAGTTTCAGCAGAGCCGCTGCAGCCATGGCCCC
B18rat      GAGTGTGGTGGGGCCCGCAGCTTCAGCAGTGCCGCGGTGACTATGGCCCC
            * ** *** **** ****** ******** ***** *   * ********

B18hum      AATCAAGGTGGGAGATGCCATCCCAGCAGTGGAGGTGTTTGAAGGGGAGC
B18rat      GATCAAGGTGGGAGACACCATTCCCTCAGTGGAGGTATTTGAAGGGGAAC
             **************  **** **  ********** *********** *

B18hum      CAGGGAACAAGGTGAACCTGGCAGAGCTGTTCAAGGGCAAGAAGGGTGTG
B18rat      CTGGAAAGAAGGTGAACTTGGCAGAGCTGTTCAAGGACAAGAAAGGTGTT
            * ** ** ********* ****************** ****** *****

B18hum      CTGTTTGGAGTTCCTGGGGCCTTCACCCCTGGATGTTCCAAGACACACCT
B18rat      TTGTTTGGAGTCCCTGGGGCATTTACACCTGGCTGTTCCAAGACCCATCT
             ********** ******** ** ** ***** *********** ** **

B18hum      GCCAGGGTTTGTGGAGCAGGCTGAGGCTCTGAAGGCCAAGGGAGTCCAGG
B18rat      GCCTGGGTTTGTGGAGCAAGCCGGAGCTCTGAAGGCCAAGGGAGCACAAG
            *** ************** ** *  ******************  ** *

B18hum      TGGTGGCCTGTCTGAGTGTTAATGATGCCTTTGTGACTGGCGAGTGGGGC
B18rat      TGGTGGCCTGTCTGAGTGTTAATGATGTCTTCGTGACTGCAGAGTGGGGT
            *************************** *** *******  ********

B18hum      CGAGCCCACAAGGCGGAAGGCAAGGTTCGGCTCCTGGCTGATCCCACTGG
B18rat      CGAGCCCACCAGGCAGAAGGCAAGGTTCAGCTCCTGGCTGACCCCACTGG
            ********* **** ************ ************ ********

B18hum      GGCCTTTGGGAAGGAGACAGACTTATTACTAGATGATTCGCTGGTGTCCA
B18rat      AGCTTTTGGAAAGGAGACAGATTTACTACTAGATGATTCTTTGGTGTCTC
             ** ***** ********** *** ************  *******

B18hum      TCTTTGGGAATCGACGTCTCAAGAGGTTCTCCATGGTGGTACAGGATGGC
B18rat      TCTTTGGGAATCGTCGGCTAAAAAGGTTCTCCATGGTGATAGACAAGGGC
            ************* ** ** ** *************** ** *  * ***

B18hum      ATAGTGAAGGCCCTGAATGTGGAACCAGATGGCACAGGCCTCACCTGCAG
B18rat      GTAGTAAAGGCACTGAACGTGGAGCCGGATGGCACAGGCCTCACCTGCAG
             **** ***** ***** ***** ** ************************

B18hum      CCTGGCACCCAATATCATCTCACAGCTCTGAGGCCCTGGGCCAGATTACT
B18rat      CCTGGCCCCCAACATCCTCTCACAACTCTGAGGCCCTGA-CCAGA--ATG
            ****** ***** *** ******* ************  *****  *

B18hum      TCCTCCACCCCTCCCTATCTCACCTGCCCAGCCCTGTGCTGG-GGCCCTG
B18rat      TCCTCTGACTCTCCC-ATCTCCTCCACCCAGCTCTGGGCCAAAGGCCCAG
            *****   * ***** *****  *  ****** *** **    ***** *

B18hum      CA------------------ATTGGAATG-----TTGGCCAGATTTCTGC
B18rat      TACCTCCTTACCTGAGGGCCACTGGAATGGAACCTTGACAATATTTCTGC
             *                  * *******     *** * * ********

B18hum      AATAAACACTTGTGGTTTGCGGAAAAAAA-------------
B18rat      AATAAACAGTT-TAATTTGTGAAAAAAAAAAAAAAAAAAAA
            ******** ** *  **** * *******
```

CLUSTAL V alignment of human and mouse cDNA sequences (Identity: 552/675, 81.8%):

FIG.5c

```
B18hum      GCCAGGAGGCGGAGTGGAAGTGGCCGTGGGGCGGGTATGGGACTAGCTGG
B18mouse    ---------------------------------------------------

B18hum      CGTGTGCGCCCTGAGACGCTCAGCGGGCTATATACTCGTCGGTGGGGCCG
B18mouse    ----------------TGCTCCGTG----------CATCGACGTGCTTG
                            **** * *          * ***  * *   *

B18hum      GCGGTCAGTCTGCGGCAGCGGCAGCAAGACGGTGCAGTGAAGGAGAGTGG
B18mouse    GCAGGCAG--------------AGCAGGCCGG---AAAGAAGCAGGTTGG
            ** * ***              **** * ***   *  **** **  ***

B18hum      GCGTCTGGCGGGGTCCGCAGTTTCAGCAGAGCCGCTGCAGCCATGGCCCC
B18mouse    GAGTGTGGCGGAGCCCGCAGCTTCAGCAGCTCCGCGGTGACCATGGCCCC
            * ** ****** * ****** ******** ****  *  **********

B18hum      AATCAAGGTGGGAGATGCCATCCCAGCAGTGGAGGTGTTTGAAGGGGAGC
B18mouse    GATCAAGGTGGGAGATGCCATTCCCTCAGTGGAGGTATTTGAAGGGGAAC
             ******************** **  ********** ********** *

B18hum      CAGGGAACAAGGTGAACCTGGCAGAGCTGTTCAAGGGCAAGAAGGGTGTG
B18mouse    CGGGAAAGAAGGTGAACTTGGCAGAGCTGTTCAAGGGCAAGAAAGGTGTT
            * ** ** ********* ************************** *****

B18hum      CTGTTTGGAGTTCCTGGGGCCTTCACCCCTGGATGTTCCAAGACACACCT
B18mouse    TTGTTTGGAGTCCCTGGGGCATTTACACCTGGCTGTTCTAAGACCCACCT
             ********** ******** ** ** ***** ***** ***** *****

B18hum      GCCAGGGTTTGTGGAGCAGGCTGAGGCTCTGAAGGCCAAGGGAGTCCAGG
B18mouse    GCCTGGGTTTGTGGAGCAAGCTGGAGCTCTGAAGGCTAAGGGAGCGCAGG
            *** ************** ****  ********** *******  ****

B18hum      TGGTGGCCTGTCTGAGTGTTAATGATGCCTTTGTGACTGGCGAGTGGGGC
B18mouse    TGGTGGCCTGTCTGAGCGTTAATGACGTCTTTGTGATTGAAGAGTGGGGT
            **************** ******** * ******** **  ********

B18hum      CGAGCCCACAAGGCGGAAGGCAAGGTTCGGCTCCTGGCTGATCCCACTGG
B18mouse    CGAGCCCACCAGGCAGAAGGCAAGGTTCGGCTCCTGGCTGACCCCACTGG
            ********* **** ************************** ********

B18hum      GGCCTTTGGGAAGGAGACAGACTTATTACTAGATGATTCGCTGGTGTCCA
B18mouse    AGCCTTTGGGAAGGCGACAGACTTATTATTGGATGATTCTTTGGTGTCTC
             ************ ************ * ********  *******

B18hum      TCTTTGGGAATCGACGTCTCAAGAGGTTCTCCATGGTGGTACAGGATGGC
B18mouse    TCTTTGGGAATCGTCGGCTGAAAAGGTTCTCCATGGTGATAGACAACGGC
            ************ ** ** ** *************** ** *  * ***

B18hum      ATAGTGAAGGCCCTGAATGTGGAACCAGATGGCACAGGCCTCACCTGCAG
B18mouse    ATAGTGAAGGCACTGAACGTGGAGCCAGATGGCACAGGCCTCACCTGCAG
            *********** ***** ***** **************************

B18hum      CCTGGCACCCAATATCATCTCACAGCTCTGAGGCCCTGGGCCAGATTACT
B18mouse    CCTGGCCCCCAACATCCTCTCCCAACTCTGAGGCCCTGG-CCAGATG---
            ****** ***** *** **** ** ************** ******

B18hum      TCCTCCACCCCTCCCTATCTCACCTGCCCAGCCCTGTGCTGGGGCCCTGC
B18mouse    TCCTCTGACTCTCCC-ATCTCTCCCACCCGGCTCT------AGGCC----
            *****   * ***** ***** **  *** ** **       ****

B18hum      AATTGGAATGTTGGCCAGATTTCTGCAATAAACACTTGTGGTTTGCGGAA
B18mouse    ----AAAAGGCTCGGTACCTCCTTACTGGGAGC-CACGT-----------
                ** * * *  *  *   * *    * * *  **
```

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:
(A) NAME: UNIVERSITE CATHOLIQUE DE LOUVAIN
Halles Universitaires
(B) STREET: Place de l' Universite, 1
(C) CITY: LOUVAIN-LA-NEUVE
(E) COUNTRY: BELGIUM
(F) POSTAL CODE (ZIP): B-1348

(A) NAME: UNIVERSITE DE MONS-HAINAUT
(B) STREET: Place du Parc 20
(C) CITY: MONS
(E) COUNTRY: BELGIUM
(F) POSTAL CODE (ZIP): B-7000

(ii) TITLE OF INVENTION: PEROXISOME-ASSOCIATED PEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID PEPTIDE'AND THEIR USES IN THE DIAGNOSTIC AND/OR THE TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS

(iii) NUMBER OF SEQUENCES: 19

(iv) COMPUTER READABLE FORM:
(A) MEDIUM TYPE: Floppy disk
(B) COMPUTER: IBM PC compatible
(C) OPERATING SYSTEM: PC-DOS/MS-DOS
(D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 805 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:193..681

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GCCAGGAGGC GGAGTGGAAG TGGCCGTGGG GCGGGTATGG GACTAGCTGG CGTGTGCGCC 60

CTGAGACGCT CAGCGGGCTA TATACTCGTC GGTGGGGCCG GCGGTCAGTC TGCGGCAGCG 120

```
GCAGCAAGAC GGTGCAGTGA AGGAGAGTGG GCGTCTGGCG GGGTCCGCAG TTTCAGCAGA      180

GCCGCTGCAG CC ATG GCC CCA ATC AAG GTG GGA GAT GCC ATC CCA GCA           228
              Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ala
                1               5                  10

GTG GAG GTG TTT GAA GGG GAG CCA GGG AAC AAG GTG AAC CTG GCA GAG        276
Val Glu Val Phe Glu Gly Glu Pro Gly Asn Lys Val Asn Leu Ala Glu
         15                  20                  25

CTG TTC AAG GGC AAG AAG GGT GTG CTG TTT GGA GTT CCT GGG GCC TTC        324
Leu Phe Lys Gly Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe
     30                  35                  40

ACC CCT GGA TGT TCC AAG ACA CAC CTG CCA GGG TTT GTG GAG CAG GCT        372
Thr Pro Gly Cys Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala
 45                  50                  55                  60

GAG GCT CTG AAG GCC AAG GGA GTC CAG GTG GTG GCC TGT CTG AGT GTT        420
Glu Ala Leu Lys Ala Lys Gly Val Gln Val Val Ala Cys Leu Ser Val
                 65                  70                  75

AAT GAT GCC TTT GTG ACT GGC GAG TGG GGC CGA GCC CAC AAG GCG GAA        468
Asn Asp Ala Phe Val Thr Gly Glu Trp Gly Arg Ala His Lys Ala Glu
             80                  85                  90

GGC AAG GTT CGG CTC CTG GCT GAT CCC ACT GGG GCC TTT GGG AAG GAG        516
Gly Lys Val Arg Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu
         95                  100                 105

ACA GAC TTA TTA CTA GAT GAT TCG CTG GTG TCC ATC TTT GGG AAT CGA        564
Thr Asp Leu Leu Leu Asp Asp Ser Leu Val Ser Ile Phe Gly Asn Arg
     110                 115                 120

CGT CTC AAG AGG TTC TCC ATG GTG GTA CAG GAT GGC ATA GTG AAG GCC        612
Arg Leu Lys Arg Phe Ser Met Val Val Gln Asp Gly Ile Val Lys Ala
125                 130                 135                 140

CTG AAT GTG GAA CCA GAT GGC ACA GGC CTC ACC TGC AGC CTG GCA CCC        660
Leu Asn Val Glu Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro
                145                 150                 155

AAT ATC ATC TCA CAG CTC TGA GGCCCTGGGC CAGATTACTT CCTCCACCCC           711
Asn Ile Ile Ser Gln Leu  *
            160

TCCCTATCTC ACCTGCCCAG CCCTGTGCTG GGGCCCTGCA ATTGGAATGT TGGCCAGATT      771

TCTGCAATAA ACACTTGTGG TTTGCGGAAA AAAA                                  805
```

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 163 amino acids
(B) TYPE: amino acid
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein
(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

```
Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ala Val Glu Val Phe
 1               5                  10                  15

Glu Gly Glu Pro Gly Asn Lys Val Asn Leu Ala Glu Leu Phe Lys Gly
            20                  25                  30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
        35                  40                  45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Glu Ala Leu Lys
    50                  55                  60

Ala Lys Gly Val Gln Val Val Ala Cys Leu Ser Val Asn Asp Ala Phe
65                  70                  75                  80

Val Thr Gly Glu Trp Gly Arg Ala His Lys Ala Glu Gly Lys Val Arg
                85                  90                  95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu Thr Asp Leu Leu
            100                 105                 110

Leu Asp Asp Ser Leu Val Ser Ile Phe Gly Asn Arg Arg Leu Lys Arg
        115                 120                 125

Phe Ser Met Val Val Gln Asp Gly Ile Val Lys Ala Leu Asn Val Glu
    130                 135                 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Ile Ser
145                 150                 155                 160

Gln Leu  *
```

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 780 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Rattus Rattus

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:136..624

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

```
TGCGTCCTAG GCAGCATAGC CGGATCGGTG CTCCGTGCAT CGGCTACTTG GACGTGCGTG      60

GCAGGCAGAG CAGGCCGGAA AGGAGCAGGT TGGGAGTGTG GTGGGGCCCG CAGCTTCAGC     120
```

AGTGCCGCGG TGACTATGGC CCCGATCAAG GTGGGAGACA CCATTCCCTC AGTGGAGGTA 180

TTTGRAGGGG AACCTGGAAA GAAGGTGAAC TTGGCAGAGC TGTTCAAGGA CAAGAAAGGT 240

GTTTTGTTTG GAGTCCCTGG GGCATTTACA CCTGGCTGTT CCAAGACCCA TCTGCCTGGG 300

TTTGTGGAGC AAGCCGGAGC TCYGAAGGCC AAGGGAGCAC AAGTGGTGGC CTGTCTGAGT 360

GTTAATGATG YCTTCGTGAC TGCAGAGTGG GGTCGAGCCC ACCAGGCAGA AGGCAAGGTT 420

CAGCTCCTGG CTGACCCCAC TGGAGCTTTT GGAAAGGAGA CAGATTTACT ACTAGATGAT 480

TCTTTGGTGT CTCTCTTTGG GAATCGTCGG CTAAAAAGGT TCTCCATGGT GATAGACAAG 540

GGCGTAGTAA AGGCACTGAA CGTGGAGCCG GATGGCACAG GCCTCACCTG CAGCCTGGCC 600

CCCAACATCC TCTCACAACT CTGAGGCCCT GACCAGAATG TCCTCTGACT CTCCCATCTC 660

CTCCACCCAG CTCTGGGCCA AAGGCCCAGT ACCTCCTTAC CTGAGGGCCA CTGGAATGGA 720

ACCTTGACAA TATTTCTGCA ATAAACAGTT TAATTTGTGA AAAAAAAAAA AAAAAAAAAA 780

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Rattus Rattus

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:17
(D) OTHER INFORMATION:/product= "Glu or Gly"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:63
(D) OTHER INFORMATION:/product= "Leu or Pro"

(ix) FEATURE:
(A) NAME/KEY: Modified-site
(B) LOCATION:79
(D) OTHER INFORMATION:/product= "Ala or Val"

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Met Ala Pro Ile Lys Val Gly Asp Thr Ile Pro Ser Val Glu Val Phe
1 5 10 15

Xaa Gly Glu Pro Gly Lys Lys Val Asn Leu Ala Glu Leu Phe Lys Asp
20 25 30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
35 40 45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Gly Ala Xaa Lys
50 55 60

Ala Lys Gly Ala Gln Val Val Ala Cys Leu Ser Val Asn Asp Xaa Phe
65 70 75 80

Val Thr Ala Glu Trp Gly Arg Ala His Gln Ala Glu Gly Lys Val Gln
85 90 95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Glu Thr Asp Leu Leu
100 105 110

Leu Asp Asp Ser Leu Val Ser Leu Phe Gly Asn Arg Arg Leu Lys Arg
115 120 125

Phe Ser Met Val Ile Asp Lys Gly Val Val Lys Ala Leu Asn Val Glu
130 135 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Leu Ser
145 150 155 160

Gln Leu

(2) INFORMATION FOR SEQ ID NO: 5:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 675 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Mouse

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:99..588

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

TGCTCCGTGC ATCGACGTGC TTGGCAGGCA GAGCAGGCCG GAAAGAAGCA GGTTGGGAGT 60

GTGGCGGAGC CCGCAGCTTC AGCAGCTCCG CGGTGACCAT GGCCCCGATC AAGGTGGGAG 120

ATGCCATTCC CTCAGTGGAG GTATTTGAAG GGGAACCGGG AAAGAAGGTG AACTTGGCAG 180

AGCTGTTCAA GGGCAAGAAA GGTGTTTTGT TTGGAGTCCC TGGGGCATTT ACACCTGGCT 240

GTTCTAAGAC CCACCTGCCT GGGTTTGTGG AGCAAGCTGG AGCTCTGAAG GCTAAGGGAG 300

CGCAGGTGGT GGCCTGTCTG AGCGTTAATG ACGTCTTTGT GATTGAAGAG TGGGGTCGAG 360

CCCACCAGGC AGAAGGCAAG GTTCGGCTCC TGGCTGACCC CACTGGAGCC TTTGGGAAGG 420

CGACAGACTT ATTATTGGAT GATTCTTTGG TGTCTCTCTT TGGGAATCGT CGGCTGAAAA 480

GGTTCTCCAT GGTGATAGAC AACGGCATAG TGAAGGCACT GAACGTGGAG CCAGATGGCA 540

CAGGCCTCAC CTGCAGCCTG GCCCCCAACA TCCTCTCCCA ACTCTGAGGC CCTGGCCAGA 600

TGTCCTCTGA CTCTCCCATC TCTCCCACCC GGCTCTAGGC CAAAAGGCTC GGTACCTCCT 660

TACTGGGAGC CACGT 675

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 162 amino acids
(B) TYPE: amino acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: peptide

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Mouse

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Ala Pro Ile Lys Val Gly Asp Ala Ile Pro Ser Val Glu Val Phe
1 5 10 15

Glu Gly Glu Pro Gly Lys Lys Val Asn Leu Ala Glu Leu Phe Lys Gly
20 25 30

Lys Lys Gly Val Leu Phe Gly Val Pro Gly Ala Phe Thr Pro Gly Cys
35 40 45

Ser Lys Thr His Leu Pro Gly Phe Val Glu Gln Ala Gly Ala Leu Lys
50 55 60

Ala Lys Gly Ala Gln Val Val Ala Cys Leu Ser Val Asn Asp Val Phe
65 70 75 80

Val Ile Glu Glu Trp Gly Arg Ala His Gln Ala Glu Gly Lys Val Arg
85 90 95

Leu Leu Ala Asp Pro Thr Gly Ala Phe Gly Lys Ala Thr Asp Leu Leu
100 105 110

Leu Asp Asp Ser Leu Val Ser Leu Phe Gly Asn Arg Arg Leu Lys Arg
115 120 125

Phe Ser Met Val Ile Asp Asn Gly Ile Val Lys Ala Leu Asn Val Glu
130 135 140

Pro Asp Gly Thr Gly Leu Thr Cys Ser Leu Ala Pro Asn Ile Leu Ser
145 150 155 160

Gln Leu

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 469 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..382

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGGTTCG 180

GCTCCTGGCT GATCCCACTG GGGCCTTTGG GAAGGAGACA GACTTATTAC TAGATGATTC 240

GCTGGTGTCC ATCTTTGGGA ATCGACGTCT CAAGAGGTTC TCCATGGTGG TACAGGATGG 300

CATAGTGAAG GCCCTGAATG TGGAACCAGA TGGCACAGGC CTCACCTGCA GCCTGGCACC 360

CAATATCATC TCACAGCTCT GAGGCCCTGG GCCAGATTAC TTCCTCCACC CCTCCCTATC 420

TCACCTGCCC AGCCGTGTGC TGGGGCCCTG CAATTGGAAT GTTGGCCAG 469

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 601 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..514

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGACACA 180

CCTGCCAGGG TTTGTGGAGC AGGCTGAGGC TCTGAAGGCC AAGGGAGTCC AGGTGGTGGC 240

CTGTCTGAGT GTTAATGATG CCTTTGTGAC TGGCGAGTGG GGCCGAGCCC ACAAGGCGGA 300

AGGCAAGGTT CGGCTCCTGG CTGATCCCAC TGGGGCCTTT GGGAAGGAGA CAGACTTATT 360

ACTAGATGAT TCGCTGGTGT CCATCTTTGG GAATCGACGT CTCAAGAGGT TCTCCATGGT 420

GGTACAGGAT GGCATAGTGA AGGCCCTGAA TGTGGAACCA GATGGCACAG GCCTCACCTG 480

CAGCCTGGCA CCCAATATCA TCTCACAGCT CTGAGGCCCT GGGCCAGATT ACTTCCTCCA 540

CCCCTCCCTA TCTCACCTGC CCAGCCCTGT GCTGGGGCCC TGCAATTGGA ATGTTGGCCA 600

G 601

(2) INFORMATION FOR SEQ ID NO: 9:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 604 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: CDS
(B) LOCATION:161..517

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9:

GGGTATGGGA CTAGCTGGCG TGTGCGCCCT GAGACGCTCA GCGGGCTATA TACTCGTCGG 60

TGGGGCCGGC GGTCAGTCTG CGGCAGCGGC AGCAAGACGG TGCAGTGAAG GAGAGTGGGC 120

GTCTGGCGGG GTCCGCAGTT TCAGCAGAGC CGCTGCAGCC ATGGCCCCAA TCAAGGTGGG 180

AGATGCCATC CCAGCAGTGG AGGTGTTTGA AGGGGAGCCA GGGAACAAGG TGAACCTGGC 240

AGAGCTGTTC AAGGGCAAGA AGGGTGTGCT GTTTGGAGTT CCTGGGGCCT TCACCCCTGG 300

ATGTTCCAAG GTTCGGCTCC TGGCTGATCC CACTGGGGCC TTTGGGAAGG AGACAGACTT 360

ATTACTAGAT GATTCGCTGG TGTCCATCTT TGGGAATCGA CGTCTCAAGA GGTTCTCCAT 420

GGTGGTACAG GATGGCATAG TGAAGGCCCT GAATGTGGAA CCAGATGGCA CAGGCCTCAC 480

CTGCAGCCTG GCACCCAATA TCATCTCACA GCTCTGAGGC CCTGGGCCAG ATTACTTCCT 540

CCACCCCTCC CTATCTCACC TGCCCAGCCC TGTGCTGGGG CCCTGCAATT GGAATGTTGG 600

CCAG 604

(2) INFORMATION FOR SEQ ID NO: 10:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 2710 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:
(A) ORGANISM: Homo sapiens

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:2516..2710

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:2074..2135

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:1932..1970

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:1728..1859

(ix) FEATURE:
(A) NAME/KEY: exon
(B) LOCATION:802..936

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10:

TCTGTCCCTT AGCGCCCCCG CGGGGGCTTA CCCCATCCCA CTCCATGACC TCCCCTCCCC 60

CCATGGCGAA TTCCCACCTT TCTGTCTTTC ACTCACTTCC TGGAACCGTC CCCAGGGCCT 120

TGGACCTTCC CCCTTCTCCT CCCAAACCTT GTGAGACCCC ATTCCCTTTC TACTTCATCC 180

TGCTCTCAAC TTTTGGGCTC CTCAGAGGCC CTCACCCCTG ACTCTCTCTC CCTACCCACT 240

CTGGTCCCAT GAAGCCCTCA AGTACTCTGG GGATGGATCC TTCCCCCTTC AAAAGATTCC 300

TTCTTTTGTT CTACACCTCC TGGGTGTAGG GGCCTGGACA CCCTCCCCCA ACGTTCCACC 360

TGCCGCTGCC CTTCCTCTTC CTCCTCCTGA GGGTGGGACC CTCAGACCTG GCCAAGATCC 420

TCTCCCTCCA TGTTGTCAGG GACTCCTCCT CACCCCCAAA TACAGCCCTC TAGCCCCTGT 480

CCATTTTATT CCACTCCTTT CCTGTAACCT AGACAGCATG TTATGCAACC CTTTGCGACA 540

CATGGGGAAA CCTTCCCTCC CTTCCTCTGT TGTCACCAAT GGCCCCTTAA GAGGAGCAGG 600

GCCACCTTGA AACTTGGAGG ATATGGGGTA ACCCAGTGGG AGCGGGCAGG GAGGGCCCTT 660

GGAAACTGAC AGGGCTGGAG TATCCTGCTG GGTTTCAGCC CCGGTTCCTG CAGGCACAGC 720

TGCCAGGCTC TCTGTTCACC TTCCTGCCTC TGGTTTGCCC CGGCTCCCTC ACCCCCCTTA 780

CCCTGGAGTC CTTCCTTCTA GGTGGGAGAT GCCATCCCAG CAGTGGAGGT GTTTGAAGGG 840

GAGCCAGGGA ACAAGGTGAA CCTGGCAGAG CTGTTCAAGG GCAAGAAGGG TGTGCTGTTT 900

GGAGTTCCTG GGGCCTTCAC CCCTGGATGT TCCAAGGTGA GGCCCTTCCC CTTCTGAAGA 960

TCAGGACCTG GGGATCTTTT GTGTTGCTCT TAAGTCCTCC ACATAGTCCT GATAGGACTC 1020

CTAAAAAGCA TTTCAGTGCC ATCACAAAAC AAGTAGAGCT GGGTAGAGCT GGGCGCGGTG 1080

GCTCACGCCT GTAATCCCAG CACTTTGGGA GGCCAAGGCG GGTGGATCAC GAGGTCAGGA 1140

GTCCAAAACC AGCCTGGCCA AGATGGTGAA ACCCTGTCTC TACTAAAAAT GCAAAAAAAT 1200

CAGCCGGATA TGGTGGCGGG CGCCTGTAAT CCCAGGTATT GGGGAGGCTG AGGCAGAGAA 1260

TTGCTTGAAC CCAGGAGGCG TAGGTTGCAG TGAGTGGAGA TCGTGCCTCT GCAGTCCAGC 1320

CTGGGTGAAA GAGCGAGACT CCGTCTCAAA ATGAAAAAAA AAAAAGAAAA CAAGTAGAGA 1380

CTGCAAAAAG GGAACAGTAC CGGGAATGTT GGAGAAAAAC ATACTACAAT TAAATCCAAC 1440

ACCCCTGTTG GTCCTGCTAA ATGACAGGCA CTGTGGAAGG TGCTTGGGAC TCAGATAAAT 1500

AAGACAAAGA TCTGCCCATG GAAAGTTCAC GTCTGGACCA TAAGGCATTA GGTTTCATTC 1560

TGAGCTTCCT AGTGGCCAAG GCAAAAAGGA AATAGAATGG TTTAGACAGC TCTCATTGTC 1620

TGATCAAAGG TGTTGAGGCA GAGCACTGAG GAGGGCCTGG AGATAAAGGG TGGGCTGGGG 1680

GTCAGATGCA GTTATCCCTT TGCCGACCCT TTGTTCCCCT TCCTCAGACA CACCTGCCAG 1740

GGTTTGTGGA GCAGGCTGAG GCTCTGAAGG CCAAGGGAGT CCAGGTGGTG GCCTGTCTGA 1800

GTGTTAATGA TGCCTTTGTG ACTGGCGAGT GGGGCCGAGC CCACAAGGCG GAAGGCAAGG 1860

TGAGGTGAGG GGCCTGCAGG GAGTCAGGAC CAGGTAGGAT ATTCTTCTTG TGACCTCTAC 1920

TTTCTCTGCA GGTTCGGCTC CTGGCTGATC CCACTGGGGC CTTTGGGAAG GTGAGTGTTC 1980

CCCTGACCGC CACAGGGACA TGGCGGTGCG GGGAGCAGTG GGGGCCCTTG GCCTCTTCAA 2040

GGATTTCTGA CACTTTTCTC TGTCTCTTCT TAGGAGACAG ACTTATTACT AGATGATTCG 2100

CTGGTGTCCA TCTTTGGGAA TCGACGTCTC AAGAGGTAAA AGTGGAGAGT CCTCTGTGGA 2160

GAAAGTCCTC TGTGGGAGAG AGTCCTCTGT GGGAGAGAGT CCTCTGTGGA GAGGGTCCTC 2220

TGTGGGAAGA GTCGTCTGTG GGGGAGATGT GTGGGAGAGA GTCCTGTGTG GGGAGAGTCT 2280

TCTGTAGGGG AGAGTCCTCT GGGGAGAGAG TCCTGTGTGG GGGAGAGTCC TCTGTGGGGA 2340

GAGTCCTCTG TGTGGAGAGA GTCCTGTGTG GTGGTGAGTC CTCTGTGGGG GAGAGTCCTC 2400

TGTGGGGGGA GTCCTCTCTG GAGTTCTCTT GGGCCCCTGG CTGTTCACTG CCTGTCTCCA 2460

TGCCCAGCCT CCAAGCCCAG GCTGATGCAG CTGGCTGGGC CCCTCTTTCC GGCAGGTTCT 2520

CCATGGTGGT ACAGGATGGC ATAGTGAAGG CCCTGAATGT GGAACCAGAT GGCACAGGCC 2580

TCACCTGCAG CCTGGCACCC AATATCATCT CACAGCTCTG AGGCCCTGGG CCAGATTACT 2640

TCCTCCACCC CTCCCTATCT CACCTGCCCA GCCCTGTGCT GGGGCCCTGC AATTGGAATG 2700

TTGGCCAGAT 2710

(2) INFORMATION FOR SEQ ID NO: 11:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 25 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11:

GCCATCCCAG CAGTGGAGGT GTTTG 25

(2) INFORMATION FOR SEQ ID NO: 12:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12:

TTGAACAGCT CTGCCAGGTT CACC 24

(2) INFORMATION FOR SEQ ID NO: 13:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 13:

TGGAGGTGTT TGAAGGGGAG CCAG 24

(2) INFORMATION FOR SEQ ID NO: 14:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 14:

CAGGTTCACC TTGTTCCCTG GCTC 24

(2) INFORMATION FOR SEQ ID NO: 15:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 20 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 15:

GGGTATGGGA CTAGCTGGCG 20

(2) INFORMATION FOR SEQ ID NO: 16:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 22 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 16:

CTGGCCAACA TTCCAATTGC AG 22

(2) INFORMATION FOR SEQ ID NO: 17:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 17:

ATGTTATGCA ACCCTTTGCG ACAC 24

(2) INFORMATION FOR SEQ ID NO: 18:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18:

GTGTTTGAAG GGGAGCCAGG GAAC 24

(2) INFORMATION FOR SEQ ID NO: 19:

(i) SEQUENCE CHARACTERISTICS:
(A) LENGTH: 24 base pairs
(B) TYPE: nucleic acid
(C) STRANDEDNESS: single
(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: DNA (genomic)

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19:

AGAGACAGGG TTTCACCATC TTGG 24

DECLARATION - USA PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am an original, first and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled PEROXISOME-ASSOCIATED POLYPEPTIDE, NUCLEOTIDE SEQUENCE ENCODING SAID POLYPEPTIDE AND THEIR USES IN THE DIAGNOSIS AND/OR TREATMENT OF LUNG INJURIES AND DISEASES, AND OF OXIDATIVE STRESS-RELATED DISORDERS; the specification of which was internationally filed on August 20, 1998, as International Application No. PCT/BE98/00124, and for which the initial documents for entry into the U.S. National Phase were filed on February 22, 2000.

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above;

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56;

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)			Priority Claimed
No.: **9700692**	Country: **Belgium**	Date Filed: **August 20, 1997**	**Yes**

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful, false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: **Bernard Knoops**

Inventor's signature X _____

Date 07-08-00

1-00

Residence: **rue Chapelle Notre-Dame 3/1, B-1341 Cernoux-Mousty, BELGIUM** BEX

Citizenship: **Belgium**

Post Office Address: **Same as Above**

2-00

Full name of Second inventor: **Cedric Hermans**

Inventor's signature X

Date 07-08-00

Residence: **avenue des Glycines 42, B-1030 Brussels, BELGIUM** BEX

Citizenship: **Belgium**

Post Office Address: **Same as Above**

3-00

Full name of Third inventor: **Alfred Bernard**

Inventor's signature X

Date 07-08-00

Residence: **avenue de la Chapelle 6, B-1200 Brussels, BELGIUM** BEX

Citizenship: **Belgium**

Post Office Address: **Same as Above**

4-00

Full name of Fourth inventor: **Ruddy Wattiez**

Inventor's signature X

Date 07-08-00

Residence: **chemin du Sauvelon 17, B-7022 Hyon, BELGIUM** BEX

Citizenship: **Belgium**

Post Office Address: **Same as Above**

5-00

Full name of Fifth inventor: **Paul Falmagne**

Inventor's signature _____

Date 07-08-00

Residence: **rue du Point du Jour 8, B-7022 Mesvin, BELGIUM** BEX

Citizenship: **Belgium**

Post Office Address: **Same as Above**

Send Correspondence To:
KNOBBE, MARTENS, OLSON & BEAR, LLP
Customer No. 20,995

H:\DOCS\JAH\JAH-2139.DOC
022800